[User]
<|image|>What are the following picture content in markdown style: <md> |  | Controls | Cases |
 | --- | --- | --- |
 | Number | 96 | 96 |
 | Age | 43.2 | 42.8 |
 | Sex (M/F) | 47/49 | 48/48

[Assistant]
|
 | Age at Diagnosis | 16.3 | 16.2 |
 | Duration T1D | 27.8 | 27.5 | </md>


[User] <|image|>Translate the image into Markdown format.

[Assistant]
<md> | Variable | <COLSPAN=2> Chronic respiratory symptoms | COR (95 % CI) | AOR (95 % CI) |
 | --- | --- | --- | --- | --- |
 |  | Yes | No |  |  |
 | <COLSPAN=5> Sex |
 | Male | 187 | 77 | 2.65(1.73,.4.05) | 2.07(1.18,3.63)* |
 | Female | 67 | 73 | 1.00 | 1.00 |
 | <COLSPAN=5> Age (years) |
 | 14-29 | 99 | 112 | 1.00 | 1.00 |
 | 30-44 | 86 | 24 | 4.05(2.39,6.87) | 3.56(1.80,7.02)*** |
 | 45+ | 69 | 14 | 5.58(2.96,10.52) | 4.20(1.94,9.12)*** |
 | <COLSPAN=5> Educational status |
 | ≤ Grade 8 | 77 | 29 | 3.46(1.93,6.20) | 4.07(1.86,8.92)*** |
 | Secondary school (Grade 9–12) | 134 | 65 | 2.69(1.64,4.41) | 2.63(1.35,5.12)** |
 | TVET and above | 43 | 56 | 1.00 | 1.00 |
 | <COLSPAN=5> Working department |
 | Raw mill | 76 | 94 | 1.00 | 1.00 |
 | Burner and clinker | 68 | 33 | 2.55(1.52,4.26) | 2.28(1.18,4.43)* |
 | Cement mill | 110 | 23 | 5.92(3.44,10.17) | 3.72(1.92,7.21)*** |
 | <COLSPAN=5> Service year |
 | ≤5 | 102 | 120 | 1.00 | 1.00 |
 | >5 | 152 | 30 | 5.96(3.72,9.56) | 5.44(3.09,9.59)*** |
 | <COLSPAN=5> Training on respiratory health |
 | Yes | 33 | 44 | 1.00 | 1.00 |
 | No | 221 | 106 | 2.78(1.67,4.62) | 2.73(1.41,5.29)** |
 | Smoking status |  |  |  |  |
 | Never smokers | 211 | 146 | 1.00 | 1.00 |
 | Ever Smokers | 43 | 4 | 7.44(2.61,21.17) | 5.38(1.42,20.39)** |
 | <COLSPAN=5> Previous chronic respiratory disease |
 | Yes | 38 | 3 | 8.62(2.61,28.45) | 7.79(2.02,30.04)*** |
 | No | 216 | 147 | 1.00 |  | </md>


[User]
<|image|>What are the following table content in markdown style: <md> |  | Time (h) | TMA | IGG | PFA |
 | --- | ---

[Assistant]
| --- | --- | --- |
 | C. albicans | 24 | 7.69 | 4.00 | 4.00 |
 | A. fumigatus |  | 33.33 | 33.33 | 4.00 |
 | C. neoformans |  | 7.69 | 33.33 | 7.69 |
 | C. albicans | 48 | 4.00 | 4.00 | 4.00 |
 | A. fumigatus |  | 33.33 | 33.33 | 4.00 |
 | C. neoformans |  | 7.69 | 33.33 | 7.69 | </md>


[User] <|image|>Convert the image into Markdown language.

[Assistant]
<md> | Outcome | HR | 95% CI | P Value |
 | --- | --- | --- | --- |
 | <COLSPAN=4> Incident MI |
 | All participants (N=991) | 2.68 | 1.86–3.85 | <0.001 |
 | Obstructive CAD (n=619) | 1.87 | 1.16–3.00 | 0.01 |
 | Nonobstructive CAD (N=226) | 8.41 | 2.77–25.5 | <0.001 |
 | <COLSPAN=4> Incident HF |
 | All participants (N=991) | 1.60 | 1.21–2.13 | 0.001 |
 | Obstructive CAD (n=619) | 1.17 | 0.76–1.80 | 0.46 |
 | Nonobstructive CAD (n=226) | 1.61 | 0.85–3.06 | 0.14 |
 | <COLSPAN=4> Cardiovascular death |
 | All participants (N=991) | 2.29 | 1.40–3.75 | 0.001 |
 | Obstructive CAD (n=619) | 2.74 | 1.48–5.06 | 0.001 |
 | Nonobstructive CAD (n=226) | 3.60 | 1.15–11.3 | 0.03 |
 | <COLSPAN=4> All‐cause death |
 | All participants (N=991) | 1.84 | 1.22–2.78 | 0.004 |
 | Obstructive CAD (n=619) | 2.06 | 1.26–3.37 | 0.004 |
 | Nonobstructive CAD (n=226) | 2.25 | 0.83–6.12 | 0.11 |
 | <COLSPAN=4> Incident MI/HF/all‐cause death |
 | All participants (N=991) | 1.62 | 1.26–2.08 | <0.001 |
 | Obstructive CAD (n=619) | 1.71 | 1.25–2.33 | <0.001 |
 | Nonobstructive CAD (n=226) | 1.60 | 0.88–2.90 | 0.12 |
 | <COLSPAN=4> Incident MI/cardiovascular death |
 | All participants (N=991) | 2.22 | 1.60–3.08 | <0.001 |
 | Obstructive CAD (n=619) | 2.06 | 1.40–3.05 | <0.001 |
 | Nonobstructive CAD (n=226) | 4.70 | 2.17–10.18 | <0.001 |
 | <COLSPAN=4> Incident MI/all‐cause death |
 | All participants (N=991) | 2.13 | 1.56–2.90 | <0.001 |
 | Obstructive CAD (n=619) | 2.06 | 1.42–2.98 | <0.001 |
 | Nonobstructive CAD (n=226) | 3.62 | 1.78–7.37 | <0.001 | </md>


[User] <|image|>Express the illustration as Markdown code.

[Assistant]
<md> | Characteristic | All studied patients | 'High-scoring patients' | 'Low-scoring patients' |
 | --- | --- | --- | --- |
 | Risk for development of PTSD, n (percentage) | 65 | 18 (29%) | 44 (71%) |
 | PTSD score (mean ± SD) | 28.1 ± 13.9 | 46.3 ± 8.9 | 20.6 ± 7.1a |
 | Age, years (mean ± SD) | 39 ± 15 | 41 ± 13 | 39 ± 15 |
 | Sex, n (male/female) | 35/30 | 8/10 | 25/19 |
 | Period between discharge and study, months (mean ± SD) | 57 ± 32 | 56 ± 33 | 59 ± 31 |
 | Lung Injury Score (mean ± SD) | 3.2 ± 0.5 | 3.3 ± 0.5 | 3.2 ± 0.5 |
 | APACHE II score (mean ± SD) | 16 ± 6 | 15 ± 4 | 16 ± 6 |
 | ICU length of stay, days (mean ± SD) | 47 ± 32 | 59 ± 37.0 | 42 ± 29b |
 | Duration of mechanical ventilation, days (mean ± SD) | 30 ± 22 | 37 ± 22 | 27 ± 22 |
 | Cause of ARDS, n (percentage within group) |  |  |  |
 | Sepsis | 13 (20) | 5 (28) | 8 (18) |
 | Pneumonia | 28 (43) | 7 (39) | 20 (45.5) |
 | Multiple trauma | 20 (31) | 5 (28) | 14 (32) |
 | Other | 4 (6) | 1 (6) | 2 (4,5) |
 | ECMO, n (percentage within group) | 7 (11) | 3 (17) | 4 (9) |
 | Current status of employment, n (percentage within group) |  |  |  |
 | Work/training | 29 (46) | 7 (39) | 22 (50) |
 | Unemployed/working at home | 5 (8) | 1 (5.5) | 4 (9) |
 | Retired | 7 (10) | 1 (5.5) | 6 (14) |
 | Disabled | 12 (18) | 8 (44) | 4 (9)b |
 | Others | 6 (13) | 1 (5.5) | 5 (11) |
 | No data | 3 (5) | - | 3 (7) | </md>


[User] <|image|>Convert the picture into Markdown language.

[Assistant]
<md> | <ROWSPAN=2> Interaction covariate | <COLSPAN=3> One‐stage | Two‐stage |
 | Amalgamated interaction (95% CI), p‐value | Within‐trial interaction (95% CI), p‐value | Across‐trial interaction (95% CI), p‐value | Within‐trial interaction (95% CI), p‐value |
 | --- | --- | --- | --- | --- |
 | Age | −0.067 (−0.094 to −0.040), <0.001 | −0.050 (−0.116 to 0.017), 0.142 | −0.071 (−0.100 to −0.041), <0.001 | −0.049 (−0.115 to 0.017), 0.142 | </md>


[User] <|image|>Transcribe the image into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Functional scale | <COLSPAN=2> Therapist-assisted | <ROWSPAN=2> P value | <COLSPAN=2> Robot-assisted | <ROWSPAN=2> P value |
 | Pre | Post | Pre | Post |
 | --- | --- | --- | --- | --- | --- | --- |
 | BBS | 27.3 ± 10.8 | 35.5 ± 14.1 | 0.012∗ | 26.6 ± 18.0 | 32.4 ± 18.8 | 0.018∗ |
 | TUG | 0 : 28 ± 0 : 11 | 0 : 22 ± 0 : 10 | 0.017∗ | 0 : 46 ± 0.40 | 0 : 27 ± 0 : 17 | 0.011∗ |
 | FIM | 80.9 ± 9.6 | 85.4 ± 8.2 | 0.016∗ | 73.9 ± 14.6 | 78.5 ± 12.9 | 0.042∗ |
 | SARA | 18.9 ± 6.8 | 15.4 ± 5.6 | 0.012∗ | 18.7 ± 7.6 | 15.2 ± 6.8 | 0.018∗ | </md>


[User] <|image|>Transform the diagram into Markdown format.

[Assistant]
<md> | Groups | Mean (SD) | Median | Min | Max |
 | --- | --- | --- | --- | --- |
 | Control | 23 (100) | 103000 | 11000 | 271000 |
 | NaOCl gel | 21 (91.3) | 1 | 0 | 17 | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | <ROWSPAN=2> Pair | <ROWSPAN=2> pol distance (%) | <COLSPAN=2> No. of env sequences | <ROWSPAN=2> env distance (%) | <COLSPAN=2> env diversity (%) | <COLSPAN=2> Infection stage |
 | T | R | T | R | T | R |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | T1–R1 | 0.24 | 28 | 23 | 1.45 | 3.05 | 0.26 | Chronic | Acute |
 | T2–R2 | 0.48 | 21 | 27 | 2.45 | 4.61 | 0.18 | Chronic | Acute |
 | T3–R3 | 0.71 | 20 | 11 | 1.49 | 3.37 | 0.10 | Chronic |

[Assistant]
Acute |
 | T4–R4 | 0.48 | 30 | 10 | 0.85 | 1.69 | 0.07 | Chronic | Acute |
 | T5–R5 | 0.23 | 18 | 19 | 0.28 | 0.93 | 0.22 | Chronic | Acute |
 | T6–R6 | 0.24 | 25 | 18 | 0.11 | 0.51 | 0.34 | Recent | Acute |
 | T7–R7 | 0.15 | 5 | 18 | 0.12 | 0.34 | 0.12 | eART-STIb | Acute |
 | T8–R8 | 0.08 | 17 | 19 | 0.32 | 0.50 | 0.11 | eART-STIb | Acute |
 | T9–R9 | 0.16 | 5a | 8 | 1.40 | 1.08 | 0.35 | Recent | Acute | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> | Case No. | ITV (cc) | PTV (cc) | <COLSPAN=2> Location |
 | --- | --- | --- | --- | --- |
 | 1 | 9.4 | 31.4 | Rt | S1 |
 | 2 | 5.1 | 22.2 | Rt | S6 |
 | 3 | 29.8 | 74.6 | Rt | S10 |
 | 4 | 8.4 | 30.3 | Rt | S3 |
 | 5 | 4.0 | 17.4 | Lt | S1+2 |
 | 6 | 9.6 | 33.0 | Rt | hilum |
 | 7 | 16.9 | 48.5 | Lt | S1+2 |
 | 8 | 15.6 | 45.7 | Lt | S10 |
 | 9 | 8.7 | 33.6 | Rt | S8

[Assistant]
|
 | 10 | 7.6 | 29.1 | Rt | S8 |
 | 11 | 7.5 | 26.7 | Rt | S8 |
 | 12 | 41.1 | 98.3 | Rt | hilum |
 | 13 | 9.7 | 33.3 | Rt | S3 |
 | 14 | 8.8 | 30.7 | Rt | S8 |
 | 15 | 42.2 | 98.8 | Lt | S1+2 |
 | 16 | 3.8 | 16.2 | Lt | S1+2 |
 | 17 | 2.3 | 12.2 | Lt | S8 |
 | 18 | 38.9 | 85.4 | Rt | S10 |
 | 19 | 2.3 | 12.1 | Rt | S5 |
 | 20 | 6.6 | 23.0 | Rt | S3 | </md>


[User] <|image|>Render the table in Markdown format.

[Assistant]
<md> | Outcomes | Screening | Screening + HPV vaccination | Incremental value | ICER (ZAR/QALY) |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> NO DISCOUNTING |
 | Total costs | ZAR 295 251 951 | ZAR 248 833 762 | ZAR −46 418 189 |  |
 | Vaccine cost | ZAR 0 | ZAR 183 228 152 | ZAR 183 228 152 |  |
 | Screening cost | ZAR 19 794 328 | ZAR 21 262 010 | ZAR 1 467 682 |  |
 | CIN1 treatment cost | ZAR 3 641 306 | ZAR 557 658 | ZAR −3 083 648 |  |
 | CIN2/3 treatment cost | ZAR 3 545 580 | ZAR 561 971 | ZAR −2 983 609 |  |
 | CC treatment cost | ZAR 268 270 736 | ZAR 43 223 970 | ZAR −225 046 766 |  |
 | Life years | 3 179 736 | 3 186 707 | 6 971 |  |
 | CC cases | 2 161 | 348 | −1 813 |  |
 | CC cancer deaths | 2 035 | 328 | −1 707 |  |
 | QALYs | 2 573 677 | 2 580 925 | 7 248 | V + S dominant |
 | <COLSPAN=5> DISCOUNTED AT 5 % |
 | Total costs | ZAR 62 169 185 | ZAR 198 527 858 | ZAR 136 358 673 |  |
 | Vaccine cost | ZAR 0 | ZAR 183 228 152 | ZAR 183 228 152 |  |
 | Screening cost | ZAR 5 766 054 | ZAR 6 223 334 | ZAR 457 279 |  |
 | CIN1 treatment cost | ZAR 1 126 206 | ZAR 177 452 | ZAR −948 755 |  |
 | CIN2/3 treatment cost | ZAR 1 183 601 | ZAR 190 676 | ZAR −992 925 |  |
 | CC treatment cost | ZAR 54 093 324 | ZAR 8 708 245 | ZAR −45 385 079 |  |
 | Life years | 1 283 817 | 1 285 076 | 1 259 |  |
 | QALYs | 1 039 522 | 1 040 852 | 1 331 | ZAR 102 479 | </md>


[User] <|image|>Express the diagram as Markdown code.

[Assistant]
<md> | <ROWSPAN=2> Case number | <ROWSPAN=2> Age (years) | <ROWSPAN=2> Sex | <ROWSPAN=2> Number of leakage points | <ROWSPAN=2> Location of leakage points | <ROWSPAN=2> Number of laser shots | <COLSPAN=2> Energy, μJ |
 | Minimum | Maximum |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | 1 | 54 | F | 2 | Extrafoveal | 7 | 120 | 140 |
 | 2 | 40 | M | 1 | Extrafoveal | 4 | 90 | 90 |
 | 3 | 48 | M | 1 | Extrafoveal | 5 | 100 | 110 |
 | 4 | 34 | M | 1 | Extrafoveal | 6 | 80 | 90 |
 | 5 | 38 | M | 1 | Extrafoveal | 5 | 105 | 120 |
 | 6 | 35 | M | 2 | Extrafoveal | 7 | 100 | 100 |
 | 7 | 45 | M | 1 | Juxtafoveal | 5 | 90 | 100 |
 | 8 | 35 | M | 1 | Extrafoveal | 4 | 95 | 100 |
 | 9 | 39 | M | 2 | Extrafoveal | 8 | 100 | 110 |
 | 10 | 50 | M | 1 | Extrafoveal | 4 | 80 | 80 |
 | 11 | 48 | M | 1 | Extrafoveal | 5 | 100 | 100 |
 | 12 | 51 | M | 2 | Extrafoveal | 5 | 95 | 110 |
 | 13 | 53 | F | 1 | Extrafoveal | 5 | 105 | 110 |
 | 14 | 53 | F | 1 | Extrafoveal | 5 | 100 | 100 |
 | 15 | 39 | M | 1 | Extrafoveal | 7 | 95 | 120 |
 | 16 | 52 | M | 1 | Extrafoveal | 5 | 90 | 90 | </md>


[User] <|image|>Transcribe the picture into Markdown format.

[Assistant]
<md> | Origin | Testing agents | Effects | Model | Ref. |
 | --- | --- | --- | --- | --- |
 | Sweet taste receptor |  |  |  |  |
 | <ROWSPAN=5> Panax ginseng | <ROWSPAN=2> Rb1 | Decrease food intake, body weight, and body fat mass; decrease fasting blood glucose; decrease blood glucose during the IPGTT; increase plasma insulin | HFD obese rats | [22] |
 | GLP-1 secretion | Human L cell line | [23] |
 | Rb2 | GLP-1 secretion | Human L cell line | [23] |
 | Re | Reduces fasting blood glucose | ob/ob mice | [24] |
 | Rg3 | Insulin secretionDecrease blood glucose during the OGTT | Rodent β cell lineICR mice | [25] |
 | Bitter taste receptor |  |  |  |  |
 | Plasmodium falciparum | Quinine | GLP-1 secretion | Human L cell line | [26] |
 | Anemarrhena asphodeloides | EA fr. | GLP-1 secretion | Human L cell line | [27] |
 | Bupleurum falcatum | HX fr. | GLP-1 secretionDecrease blood glucose during the OGTT | Human L cell linedb/db mice | [28] |
 | Citrus aurantium | HX fr. | GLP-1 secretion | Human L cell line | [29] |
 | <ROWSPAN=2> Gentiana scabra | ExtractLoganic acid | GLP-1 secretion | Human L cell line | <ROWSPAN=2> [30] |
 | Extract | Increase plasma GLP-1 and plasma insulin; decrease blood glucose during the OGTT | db/db mice |
 | Cannabinoid receptor |  |  |  |  |
 | <ROWSPAN=2> Hoodia extract | <ROWSPAN=2> ExtractGordonoside F | Decreases blood glucose during the OGTT; increases plasma GLP-1 and insulin; decreases cumulative food intake | C57BL/6 mice | <ROWSPAN=2> [31] |
 | Glucose stimulated insulin secretion | Isolated rat islets |
 | Bile acid receptor |  |  |  |  |
 | Panax ginseng | Compound K | GLP-1 secretion | Human L cell line | [32] | </md>


[User] <|image|>Interpret the diagram as Markdown format.

[Assistant]
<md> | Gene | Fold-change of down-regulation in response to 1% O2* |
 | --- | --- |
 | cards1 | 4.93 ± 0.78† |
 | glpF | 1.67 ± 0.88 |
 | katE | 5.37 ± 2.60† |
 | sodA | 1.35 ± 1.06 | </md>


[User]
<|image|>Parse the diagram content behind with markdown code: <md> |  | <COLSPAN=2> Gender | Overall (N = 108) |
 | (Cronbach’s α 0.845) | Female (N = 84) | Male (N = 24) | Male and female |
 | --- | --- | --- | --- |
 | 1. Standardized (e.g. simulated) patients’ assessment of their interactions with students | 6.84 ± 1.70 | 7.04 ± 1.68 | 6.89 ± 1.69 |
 | 2. Faculty direct observation of students’ interactions with actual patients | 7.60 ± 1.31 | 7.67 ± 1.13 | 7.62 ± 1.26 |
 | 3. Faculty observation of videotaped interactions of students with actual patients | 6.45 ± 2.04 | 6.46 ± 2.13 | 6.45 ± 2.05 |
 | 4. Faculty observation of students’ interactions with clinical team members | 7.31 ± 1.51 | 7.29 ± 1.33 | 7.31 ± 1.46 |
 | 5. Students’ written and observational skills in analyzing ‘trigger’ videotapes | 5.77 ± 2.14 | 5.92 ± 1.56 | 5.80 ± 2.02 |

[Assistant]
| 6. Written exercises as follow-ups to standardized (e.g., simulated) patient interactions | 5.73 ± 1.95 | 6.00 ± 2.00 | 5.79 ± 1.95 |
 | 7. Evaluation of students by non-faculty staff | 6.54 ± 1.98 | 6.33 ± 2.60 | 6.50 ± 2.12 |
 | 8. Evaluation of students by patients | 7.20 ± 1.99 | 7.13 ± 2.86 | 7.19 ± 2.20 |
 | Group means | 6.68 ± 1.31 | 6.73 ± 1.28 | 6.69 ± 1.30 | </md>


[User] <|image|>Convert the diagram into Markdown format.

[Assistant]
<md> | Number | Constituent | RT (min) | Peak area (%) |
 | --- | --- | --- | --- |
 | 1 | α-Phellandrene | 9.02 | 0.081 |
 | 2 | α-Pinene | 9.28 | 0.159 |
 | 3 | β-Pinene | 10.91 | 11.438 |
 | 4 | α-Myrcene | 11.01 | 0.146 |
 | 5 | Terpinolene | 11.66 | 0.018 |
 | 6 | Limonene | 12.37 | 0.049 |
 | 7 | β-Phellandrene | 12.70 | 0.037 |
 | 8 | Benzene | 12.85 | 2.642 |
 | 9 | Eucalyptol | 13.05 | 0.037 |
 | 10 | γ-Terpinene | 13.44 | 10.698 |
 | 11 | Linalool | 16.58 | 0.011 |
 | 12 | 2,6-Dimethyl-3,5,7-octatriene-2-ol | 19.10 | 0.011 |
 | 13 | 4-Methyl-1-(1-methylethyl)- | 19.43 | 0.031 |
 | 14 | 1,3-Cyclohexadiene-1-methanol | 20.37 | 2.023 |
 | 15 | Cuminaldehyde | 23.18 | 48.773 |
 | 16 | 3-Cyclohexene-1-carboxaldehyde, 1,3,4-trimethyl- | 24.07 | 0.064 |
 | 17 | 1H-Cyclopropa[a]naphthalene,1a,2,3,5,6,7,7a,7b-octahydro-1,1,7,7a-tetramethyl-, [1aR-(1aà,7à,7aà,7bà)]- | 24.26 | 0.034 |
 | 18 | 3-Caren-10-al | 24.59 | 14.000 |
 | 19 | 2-Caren-10-al | 24.77 | 9.355 |
 | 20 | Benzenemethanol, 4-(1-methylethyl)- | 25.35 | 0.078 |
 | 21 | Bicyclo[3.1.1]hept-2-ene-2-methanol, 6,6-dimethyl- | 25.85 | 0.016 |
 | 22 | cis-à-Bisabolene | 26.29 | 0.026 |
 | 23 | 1,6,10-Dodecatriene, 7,11-dimethyl-3-methylene-, (E)- | 26.52 | 0.029 |
 | 24 | γ-Elemene | 27.70 | 0.031 |
 | 25 | Naphthalene | 27.78 | 0.012 |
 | 26 | Carotol | 31.81 | 0.011 |
 |  | Total identified |  | 99.81 | </md>


[User] <|image|>Translate the illustration into Markdown format.

[Assistant]
<md> |  | CM | SC | Pvalue |
 |  | (n=18) | (n=156) |  |
 | --- | --- | --- | --- |
 | Operation time (min) |  |  |  |
 | Mean | 129±34 | 108±48 | 0.084 |
 | Range | 63–190 | 50–375 |  |
 | Amount of bleeding (mL) |  |  |  |
 | Mean | 146.7±185.2 | 79.7±236.4 | 0.247 |
 | Range | 0–675 | 0–1970 |  |
 | Success rate of |  |  | <0.001 |
 | intraoperative cholangiography |  |  |  |
 | Possible | 9 | 145 |  |
 | Not possible | 9 | 11 |  |
 | Site of proximal bile duct stump |  |  | <0.001 |
 | Cystic duct | 11 | 148 |  |
 | Neck of gallbladder | 7 | 8 |  |
 | Methodology of treatment |  |  |  |
 | for bile duct stump |  |  |  |
 | Clip | 6 | 131 | <0.001 |
 | Endoloop | 1 | 2 |  |
 | Ligation | 4 | 7 |  |
 | Suture | 3 | 6 |  |
 | Elastic yarn (for transcystic drainage) | 2 | 10 |  |
 | None | 2 | 0 |  |
 | Conversion rate (%) | 6/17(35.3) | 7/146(4.8) | <0.001 | </md>


[User] <|image|>Transcribe the illustration into Markdown format.

[Assistant]
<md> | Rank | AFX_1 | AFX_2 | ABI | AG1 | GEH |
 | --- | --- | --- | --- | --- | --- |
 | 1 | neoplasia | tumor | tumor | cancer | tumorigenesis |
 | 2 | cancer | cancer | cancer | tumorigenesis | neoplasia |
 | 3 | tumor | primary tumor | neoplasia | neoplasia | cancer |
 | 4 | primary tumor | malignant tumor | primary tumor | tumor | tumor |
 | 5 | malignant tumor | carcinoma | malignant tumor | primary tumor | primary tumor |
 | 6 | carcinoma | inflammatory response | carcinoma | malignant tumor | malignant tumor |
 | 7 | colorectal cancer | immune response | genetic disorder | carcinoma | carcinoma |
 | 8 | inflammatory response | digestive organ tumor | digestive organ tumor | digestive organ tumor | inflammatory response |
 | 9 | morphogenesis | dermatological disorder | inflammatory disorder | inflammatory disorder | colorectal cancer |
 | 10 | immunological disorder | inflammatory disorder | colorectal cancer | immunological disorder | endometriosis | </md>


[User] <|image|>Translate the photo into Markdown format.

[Assistant]
<md> |  | Family planning services | Disease specific approach | Capacity building approach | Use of ICT | Support of research initiatives |
 | --- | --- | --- | --- | --- | --- |
 | Random effects |  |  |  |  |  |
 | Between donors (within donors) | 1.07 (1.03) | 0.71 (0.84) | 1.02 (1.01) | 1.44 (1.20) | 1.24 (1.11) |
 | Fixed effects |  |  |  |  |  |
 | (Intercept) | −0.14 (0.50) | −1.83*** (0.47) | 0.70 (0.50) | −3.68*** (0.80) | −2.67*** (0.62) |
 | Corporations | −1.31# (0.77) | 0.09 (0.75) | 1.42# (0.85) | 2.71** (1.05) | −0.30 (1.06) |
 | Foundations | −2.36** (0.90) | −1.50# v | −1.85* (0.74) | 1.31 (1.05) | 2.66** (0.85) |
 | AIC | 310.2 | 207 | 288.7 | 184.4 | 205.6 | </md>


[User] <|image|>Convert the table into Markdown language.

[Assistant]
<md> | Study | Region | Diagnostic criteria | Prevalence (per million population) | Prevalence > 50 yrs (per million population) |
 | --- | --- | --- | --- | --- |
 | Lingberg et al.[2] | Sweden | Biopsy and clinical data | 2.2 | n/a |
 | Kaipiainen-Seppanen and Aho[4] | Finland | Not mentioned | 0.9 | n/a |
 | Philips et al.[5] | Australia | Griggs et al. criteria | 9.3 | 35.3 |
 | Badrising et al.[3] | Netherlands | ENMC criteria | 4.9 | 16 |
 | Felice and North (Connecticut, USA)[6] | Connecticut, USA | Griggs et al. criteria | 10.7 | 28.9 (>45 yrs) |
 | Needham et al.[1] | Western Australia | Clinical and biopsy criteria | 14.9 | 51.2 |
 | Wilson et al.[7] | Olmsted County, USA | Griggs et al. criteria | 71 | n/a |
 | Oflazer et al.[8] | Istanbul, Turkey | Own criteria from the study (biopsy and clinical data) | 1.0 | 6.0 |
 | <ROWSPAN=2> Suzuki et al.[9] | <ROWSPAN=2> Japan | <ROWSPAN=2> Clinical and biopsy criteria | 1.3 (in 1991) | n/a |
 | 9.8 (in 2003) | n/a |
 | Tan et al.[10] | South Australia | Biopsy and clinical data | 50.5 | 139.3 | </md>


[User]
<|image|>Parse the photo content behind with markdown code: <md> | Gene set | Number of genes | Enrichment Score | P-value | Qvalue | Rank |
 | --- | --- | --- | --- | --- | --- |
 | Cilia-microtubule function | 8 | 2.05 | 2.1 × 10−8 | 0.01 | 1 |
 | Reactome loss of nlp from mitotic centrosomes | 27 | 1.93 | 3.1 × 10−4 | 0.11 | 2 |
 | Chromosome segregation | 16 | 1.84 | 1.8 × 10−3 | 0.37 | 3 |
 | Reactome recruitment of mitotic centrosome proteins and complexes | 31 | 1.83 | 6.7 × 10−4 | 0.34 | 4 |
 | Reactome glutathione conjugation | 10 | 1.82 | 2.2 × 10−3 | 0.34 | 5 |
 | Response to light stimulus | 23 | 1.81 | 2.1 × 10−3 | 0.33 | 6 |
 | Respiratory gaseous exchange | 6 | 1.80 | 8.3 × 10−4 | 0.31 | 7 |
 | Response to radiation | 29 | 1.78 | 2.8 × 10−3 | 0.37 | 8 |
 | Kegg abc transporters | 30 | 1.78 | 2.1 × 10−3 | 0.36 | 9 |
 | Response to ultraviolet | 15 | 1.76 | 6.1 × 10−3 | 0.41 | 10 |
 | Photoreceptor cell maintenance | 7 | 1.75 | 3.8 × 10−3 | 0.45 | 11 |
 | Chromosome organization and biogenesis | 41 | 1.74 | 1.7 × 10−3 | 0.46 | 12 |
 | Regulation of

[Assistant]
endocytosis | 6 | 1.72 | 4.4 × 10−3 | 0.55 | 13 |
 | Reactome mitotic g2 g2 m phases | 35 | 1.72 | 4.1 × 10−3 | 0.54 | 14 |
 | Membrane fusion | 11 | 1.71 | 9.4 × 10−3 | 0.52 | 15 | </md>


[User] <|image|>Continue parse the illustration with markdown style: <md> | Gene Name | Forward Primer (5'-3') |

[Assistant]
Reverse Primer (5'-3') |
 | --- | --- | --- |
 | Claudin-2 | GACCCCTAAGGCTGAGGAAC | AGAAGAGGAGGCCCAAGGAAG |
 | Cdx-2 | GCCAGGTCCTCTGAGAAGTG | CCTCTGAGAGCCAGGTCTGT |
 | Cdx-2-siRNA | GACAAGGACGUGAGCAUGUACCCUA | UAGGGUACAUGCUCACGUCCUUGUC |
 | 18srRNA | AAACGGCTACCACATCCAAG | TAACGAGGATCCATTGGAGG | </md>


[User]
<|image|>Parse the following content of the illustration in markdown code: <md> | Predictor | Coefficient B | 95% confidence interval for B | P value |
 | --- | --- | --- | --- |
 | PCS on entry into prison | -0.45 | -0.67 to -0.24 | <0.001 |
 | Age | -0.17 | -0.39 to 0.07 | 0.16 |
 | Self reported ethnicity: white | 4.56 | -0.43 to 9.55 | 0.073 |
 | Left school aged 16 years or less | 3.20 | -2.58 to 8.98 | 0.27 |
 | Unemployed before coming into prison | -0.27 | -5.98 to 5.44 | 0.93 |
 | Has been in prison before | 0.52 | -5.15 to

[Assistant]
6.20 | 0.85 |
 | Intravenous drug use in week prior to imprisonment | 5.69 | -2.65 to 14.04 | 0.18 | </md>


[User]
<|image|>Parse the following content of the image in markdown code: <md> |  |  | Preoperative | Postoperative | Difference | p-value |
 | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=2> RA | base | - 11 ± 3 | - 5 ± 2 | 6 ± 3 | <0.001 |
 | mid | - 10 ± 3 | - 4 ± 2 | 6 ± 3 | <0.001 |
 | <ROWSPAN=2> IAS | base | - 7 ± 2 | - 6 ± 2 | 1 ± 2 | <0.001 |
 | mid | - 7 ± 2

[Assistant]
| - 5 ± 2 | 2 ± 2 | <0.001 |
 | <ROWSPAN=2> LA lat | base | - 8 ± 2 | - 6 ± 2 | 2 ± 2 | <0.001 |
 | mid | - 8 ± 3 | - 5 ± 2 | 3 ± 2 | <0.001 |
 | LA post | base | - 8 ± 2 | - 6 ± 2 | 2 ± 2 | 0.002 |
 |  | mid | - 6 ± 2 | - 4 ± 1 | 2 ± 3 | <0.001 | </md>


[User]
<|image|>What are the following diagram content in markdown style: <md> | <ROWSPAN=2> Species | <COLSPAN=4> Concentration |
 | 100 mg·mL−1 | 50 mg·mL−1 | 10 mg·mL−1 | 1 mg·mL−1 |
 | --- | --- | --- | --- | --- |
 | M.

[Assistant] piperita | 7.6 ± 0.57 | 7 ± 0.0 | 9 ± 1.0 | 7.3 ± 0.57 | </md>


[User]
<|image|>What are the following picture content in markdown style: <md> |  | Mean (SD) | Response rate (%) | Floora (%) | Ceilingb (%) |
 | --- | --- | --- | --- | --- |
 | Pain | 55.4 (22.3) | 98 | 0 | 2 |
 | Symptoms | 53.3 (13.4) | 100 | 0 | 0 |
 | Activities of Daily Living | 67.4 (23.0) | 100 | 0 |

[Assistant]
3 |
 | Sport and Recreation Function | 32.9 (25.9) | 98 | 9 | 3 |
 | Knee-related Quality of Life | 32.3 (22.5) | 100 | 7 | 2 | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> | Motif number | Length (aa) | Conserved sequence |
 | --- | --- | --- |
 | motif1 | 30 | PGAFVVNVGDTLQALSNGRFKSVLHRVVVN |
 | motif2 | 18 | HTDPTILTILHQDQVGGL |
 | motif3 | 30 | ARLVVKACEEWGFFQVVNHGVPAELISRAE |
 | motif4 |

[Assistant]
19 | FEESDSILRLNHYPPCPEP |
 | motif5 | 19 | RLYRDFTWSEYLEFTQKHY |
 | motif6 | 19 | RLSMAYFLGPPLDKVISPL |
 | motif7 | 30 | GPPDPFGYGSKRIGPNGDVGWLEYLLLNTN |
 | motif8 | 19 | VVEEYCEAMKKLALKLLEL |
 | motif9 | 14 | RFSSKLPWKETLSF |
 | motif10 | 30 | DRFFALPLSQKQKAQRSPGEVCGYASAFIG |
 | motif11 | 14 | RADMNTLDAFSNWL |
 | motif12 | 30 | LSNGSYRWGTPTATSLRQLSWSEAFHIPLT |
 | motif13 | 19 | SVKDYFRKTWGNDFEQFGK |
 | motif14 | 19 | SEAYREHPLHLKHIIPLDF |
 | motif15 | 10 | LGDNRLGPFE | </md>


[User]
<|image|>Parse the table content behind with markdown code: <md> |  | OBS | SHY | PAS | MOODS | ABS |
 | --- | --- | --- | --- | --- | --- |
 | Global well-being | 26.80∗∗ | 27.58∗∗ | 32.79 | 29.07 | 27.25∗ |
 | IBS well-being | 4.60∗∗ | 10.32 | 8.24 | 6.30∗ | 4.00∗∗ |
 | FB well-being | 5.20 | 1.61∗ | 2.50 | 4.63 | 2.50 |
 | FD well-being | 11.20 | 13.70 | 13.82 | 11.85 |

[Assistant]
13.50 |
 | FC well-being | 5.80 | 1.94∗ | 8.23 | 6.30 | 7.25 | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> | Characteristic | Value |
 | --- | --- |
 | Age (years) |  |
 | Median | 73 |
 | Range | 42-89 |
 | Tumor size (cm) |  |
 | Median | 1.0 |
 | Range | 0.1-3.5 |
 | Histology |  |
 | Invasive ductal | 213 (68%) |
 | Invasive lobular | 31 (10%) |
 | DCIS | 68 (22%) |
 | Grade |  |
 | Grade 1 | 142 (46%) |
 | Grade 2 | 114 (37%) |
 | Grade 3 | 53 (17%) |
 | Not stated | 3 (1%) |
 | Invasive tumors - EIC present |  |
 | Yes | 34 (14%) |
 | No | 206 (84%) |
 | Not stated | 4 (2%) |
 | Invasive tumors - LVI present |  |
 | Yes | 5 (2%) |
 | No | 235 (96%) |
 | Not stated | 4 (2%) |
 | DCIS tumors - Necrosis present |  |
 | Yes | 36 (53%) |
 | No | 28 (41%) |
 | Not stated | 4 (6%) |
 | Nodal Status of invasive cancer |  |
 | N0 | 207 (85%) |
 | N1 | 2 (1%) |
 | Nx | 35 (14%) |
 | ER/PR status |  |
 | Positive | 282 (90%) |
 | Negative | 23 (7%) |
 | Not stated | 7 (2%) |
 | HER-2/neu status of invasive cancer |  |
 | Positive | 11 (5%) |
 | Negative | 231 (95%) |
 | Not stated | 2 (1%) |
 | Surgical margins |  |
 | Negative (≥

[Assistant]
2 mm) | 264 (85%) |
 | Close (< 2 mm) | 41 (13%) |
 | Positive | 7 (2%) |
 | Chemotherapy |  |
 | Yes | 7 (2%) |
 | No | 305 (98%) |
 | Hormonal therapy |  |
 | Yes | 166 (53%) |
 | No | 146 (47%) | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> |  | Total length (bp) | No. | Max length(bp) | Average length (bp) | N50 | GC % |
 | --- | --- | --- | --- | --- | --- | --- |
 | Contig | 92,485,665 | 273,199 | 17,250 | 338.53 | 409 | 46.05 |
 | Transcript | 84,205,775 | 162,496 | 17,250 | 518 | 634 | 43.60 |

[Assistant] | Unigene | 21,739,745 | 25,925 | 17,250 | 839 | 1,250 | 39.51 | </md>


[User]
<|image|>What are the following table content in markdown style: <md> |  | <COLSPAN=2> 2000 | <COLSPAN=2> 2009 |
 |  | Number of visit | Percentage | Number of visit | Percentage |
 | --- | --- | --- | --- | --- |
 | 0-6 Y/O | 93210 | 53.4 | 62703 | 44.1 |
 | 7-18 Y/O |

[Assistant]
81441 | 46.6 | 79497 | 55.9 |
 | Total | 174651 |  | 142200 |  |
 | Male | 92386 | 52.9 | 75689 | 53.2 |
 | Female | 82005 | 47.0 | 66497 | 46.8 |
 | Missing | 260 | 0.1 | 14 | 0.0 | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> | Characteristics | Females [n (%)] | Males [n (%)] |
 | --- | --- | --- |
 | Age (years) at baselinea* | 30.0 ± 4.1 | 31.8 ± 4.9 |
 | BMI at baseline* |
 | Under/healthy (BMI < 25) | 229 (46) | 84 (17) |
 | Overweight (25 ≤ BMI < 30) | 136 (27) | 206 (42) |
 | Obese (30 ≤ BMI < 35) | 66 (13) | 131 (26) |
 | Morbidly obese (BMI ≥ 35) | 69 (14) | 75 (15) |
 | Missing values | 1 (< 1) | 5 (< 1) |
 | Mean ± SD* | 27.6 ± 7.3 | 29.8 ± 5.6 |
 | Race/Ethnicity |
 | Non-Hispanic white | 393 (79) | 394 (79) |
 | Non-Hispanic black | 24 (5) | 23 (5) |
 | Hispanic | 50 (10) | 45 (9) |
 | Other | 31 (6) | 36 (7) |
 | Missing values | 3 (< 1) | 3 (< 1) |
 | Household income |
 | < $70,000 | 157 (32) | 163 (33) |
 | ≥ $70,000 | 334 (68) | 328 (67) |
 | Missing values | 10 (2) | 10 (2) |
 | Parity conditional on gravidity |
 | No prior pregnancy | 210 (42) |

[Assistant]
215 (43) |
 | Prior pregnancy |
 | Without live birth(s) | 53 (11) | 44 (9) |
 | With live birth(s) | 235 (47) | 239 (48) |
 | Missing values | 3 (< 1) | 3 (< 1) |
 | Active smoking status* |
 | Yes (serum cotinine ≥ 10 ng/mL) | 58 (12) | 106 (22) |
 | No (serum cotinine < 10 ng/mL) | 431 (88) | 387 (79) |
 | Missing values | 12 (2) | 9 (2) |
 | <COLSPAN=3> BMI, body mass index (kg/m2). aMean ± SD. *p < 0.05 from independent t-test for continuous characteristics or chi-square test for categorical characteristics. | </md>


[User]
<|image|>What are the following diagram content in markdown style: <md> | Variable | Body Weight (Kg) | Total Body Fat (Kg) | Trunk Fat (Kg) |
 | --- | --- | --- | --- |
 | EGG |  |  |  |
 | Baseline | 98.9 ± 15.3 | 30.2 ± 8.0 | 18.6 ± 5.5 |
 | 12 Weeks | 92.2 ± 12.7 | 25.4 ± 8.4 | 15.3 ± 5.7 |
 | SUB |  |  |  |
 | Baseline | 97.6 ± 19.9 | 31.6 ± 12.4 | 19.8 ± 7.8 |
 | 12 Weeks | 91.7 ± 15.7 | 27.0 ± 12.0 | 16.6 ± 7.4 |
 | Time Effect | P < 0.0001 | P < 0.0001 |

[Assistant]
P < 0.0001 |
 | Diet Effect | NS | NS | NS |
 | Interaction | NS | NS | NS | </md>


[User]
<|image|>Parse the following content of the illustration in markdown code: <md> | Treatments | Biomass (g) | Shoot Biomass (g) | Root Biomass (g) | Pn (μmol CO2·m−2·s−1) | Nodule Number per Plant | Dry Weight per Nodule (mg) |
 | --- | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=7> Maize |
 | NS | 118.40 ± 6.26a | 95.13 ± 4.71a | 23.27 ± 1.55a | 40.38 ± 1.81a | / | / |
 | SS | 120.22 ± 5.56a | 94.95 ± 4.81a | 25.27 ± 0.75a | 40.23 ± 3.52a | / | / |
 | CS | 94.19 ± 2.98b | 76.16 ± 2.58b | 18.03 ± 0.40b | 34.48 ± 1.08b | / | / |
 | <COLSPAN=7> Peanut |
 | NS | 13.95 ± 0.99a | 12.36 ± 0.76a | 1.59

[Assistant]
± 0.23a | 26.60 ± 1.53a | 528.33 ± 25.42a | 0.51 ± 0.03ab |
 | SS | 14.60 ± 1.07a | 12.83 ± 0.70a | 1.77 ± 0.37a | 27.60 ± 1.63a | 626.00 ± 40.00a | 0.57 ± 0.06a |
 | CS | 14.30 ± 0.72a | 13.17 ± 0.66a | 1.13 ± 0.06b | 24.98 ± 1.67a | 310.00 ± 50.20b | 0.43 ± 0.04b | </md>


[User]
<|image|>Continue parse the illustration with markdown style: <md> |  | Low | Intermediate | High | Mean score |
 | --- | --- | --- | --- | --- |
 | Hospital physicians | 8

[Assistant]
(4–15) | 15 | 77 (68–85) | 6.39 (6.04–6.73) |
 | General Practitioners | 15 (9–24) | 26 | 59 (49–69) | 5.74 (5.35–6.13) |
 | Public Health Nurses | 6 (2–13) | 23 | 71 (61–80) | 6.28 (5.97–6.58) |
 | Both panels together | 8 (4–15) | 22 | 70 (60–79) | 6.27 (5.96–6.58) | </md>


[User] <|image|>Convert the figure into Markdown format.

[Assistant]
<md> | Study | N subjects | Place of stimulation | Number of sessions | Length | Frequency | Intensity of stimulation | Sham stimulation | Assessment | Findings |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Camprodon et al. (2007) [55] | 6 | Bilateral DLPFC | 2 sessions | 20 trains of 10 s | 10 Hz | 90% MT | No | Craving, anxiety, happiness, sadness, and discomfort, assessed by VAS | Reduction in craving (with right DLPFC rTMS); reduction in anxiety after right-sided rTMS; increase in happiness after right-sided and in sadness after left-sided rTMS; increase in discomfort equally by left- and right-sided stimulation |
 | Politi et al. (2008) [56] | 36 | Left DLPFC | 10 daily sessions | 20 trains of 2 s | 15 Hz | 100% MT | No | Clinical assessment of craving related symptoms | Reduction in craving | </md>


[User] <|image|>Convert the picture into Markdown language.

[Assistant]
<md> |  | <COLSPAN=3> Number of pen samples by the categories of the outcome variable |  | <COLSPAN=3> Number of pen samples by the categories of the outcome variable |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 |  | 1 | 2 | 3 |  | 1 | 2 | 3 |
 | <COLSPAN=8> PEN VARIABLES |
 | The pen has direct access to outside |  |  |  | Sanitary gap before breeders entering |  |  |  |
 | No | 1146 | 30 | 92 | No | 626 | 19 | 44 |
 | Yes | 354 | 16 | 32 | Yes | 874 | 27 | 80 |
 | Individual pen |  |  |  | Feed |  |  |  |
 | No | 1194 | 41 | 98 | Dry pellet | 229 | 7 | 27 |
 | Yes | 306 | 5 | 24 | Dry non pellet | 1230 | 36 | 97 |
 | Missing observations | 0 | 0 | 2 | Wet | 41 | 3 | 0 |
 | Diarrhoea in the last 3 months |  |  |  | Floor |  |  |  |
 | No | 1445 | 45 | 118 | Fully slatted | 139 | 5 | 10 |
 | Yes | 33 | 1 | 2 | Others | 1361 | 41 | 114 |
 | Missing observations | 22 | 0 | 4 | Source of feed |  |  |  |
 | Age of the breeding sows |  |  |  | Exclusively own | 199 | 8 | 8 |
 | Only gilts or gilts and others | 874 | 38 | 73 | Bought + Mixture | 1301 | 38 | 116 |
 | Without gilts | 626 | 8 | 51 | Potential Salmonella control substances added to water |  |  |  |
 | Sex of the breeding pigs |  |  |  | No | 1291 | 38 | 111 |
 | Only females | 1430 | 44 | 114 | Yes | 209 | 8 | 13 |
 | Males and females | 70 | 2 | 10 | Use of antibiotics in the last 4 weeks in breeders |  |  |  |
 | Breeding sector |  |  |  | No | 1229 | 45 | 103 |
 | Mating room | 210 | 10 | 21 | Yes | 271 | 1 | 21 |
 | Gestation room | 789 | 26 | 62 | Way how was collected the sample |  |  |  |
 | Mixture of room | 58 | 1 | 14 | Compose sample | 121 | 1 | 11 |
 | Farrowing room | 390 | 7 | 22 | Swab | 1379 | 45 | 113 |
 | Replacement breeders | 44 | 2 | 5 | Number of pigs in the pen |  |  |  |
 |  |  |  |  | =10 | 1284 | 34 | 94 |
 |  |  |  |  | >10 | 216 | 12 | 30 | </md>


[User]
<|image|>Continue parse the image with markdown style: <md> | Sites of recurrence | Frequency |
 | --- | --- |
 | Lymph nodes | 38 (71.7%) |
 | Supradiaphragmatic | 5 |
 | Supra and infradiaphragmatic | 12 |
 | Pelvis | 7 (13.2%) |
 | Liver | 10

[Assistant]
(18.9%) |
 | Bone | 2 (3.7%) |
 | Lung | 4 (7.5%) |
 | Peritoneal lesion | 16 (30.2%) | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | Sampling location | Sample abbreviation | Freq. of Pan IA | Pan I genotype | No of fish |
 | --- | --- | --- | --- | --- |
 | Båtsfjord | NEAC | 0.125 |

[Assistant]
BB | 45 |
 | Malangen | NCC-N | 0.872 | AA | 11 |
 | Molde | NCC-S1 | 0.966 | AA | 30 |
 | Florø/Nærøysund | NCC-S2 | 0.980 | AA | 9 | </md>


[User] <|image|>Transcribe the diagram into Markdown format.

[Assistant]
<md> | County of residence | Records reviewed | County errors (%) | Zip code errors (%) |
 | --- | --- | --- | --- |
 | Potter | 243 | 2 (0.82) | 14 (5.8) |
 | Randall | 111 | 16 (14.4) | 7 (6.3) | </md>


[User] <|image|>Express the diagram as Markdown code.

[Assistant]
<md> | Trait | Unit | Biological importance | n | AVG | SD | max | min |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | Body weight | kg |  | 162 | 51 | 9.0 | 31 | 77 |
 | Carcass weight | kg |  | 165 | 28 | 4.4 | 16 | 40 |
 | Dressing percentage | % | Proportion final weight to carcass weight | 161 | 55 | 3 | 71 | 46 |
 | Total fat | kg | Indicator of total fatness | 165 | 14 | 5.6 | 4.6 | 33 |
 | Carcass fat | kg | Indicator of carcass fatness | 165 | 8.7 | 2.4 | 3.5 | 18 |
 | Internal fat | kg | Indicator of fatness in the internal depots | 165 | 3.8 | 1.6 | 1.1 | 8.8 |
 | Percent fat in carcass | % | Proportion of fat in the carcass | 165 | 31 | 4 | 22 | 45 |
 | Subcutaneous fat depth* | Pixel | Indicator of fatness | 161 | 5.9 | 2.3 | 1 | 13 |
 | Subcutaneous fat area | mm2 | Indicator of fatness | 165 | 980 | 480 | 36 | 2597 |
 | Total lean | kg | Indicator of total lean | 152 | 22 | 5.61 | 12 | 32 |
 | Carcass lean | kg | Indicator of muscularity | 165 | 16 | 2.34 | 10 | 22 |
 | Percent lean in carcass | % | Proportion of lean in carcass | 165 | 59 | 3 | 48 | 67 |
 | Eye muscle area* | mm2 | Indicator of muscularity | 165 | 4205 | 502 | 1245 | 5333 |
 | Total bone | kg | Indicator of total bone | 152 | 7.4 | 4.4 | 2.5 | 12 |
 | Carcass bone | kg | Indicator of size/quantity of bone | 165 | 2.9 | 0.34 | 1.98 | 4.2 |
 | Percent bone in carcass | % | Proportion of bone in carcass | 165 | 11 | 2 | 7 | 16 | </md>


[User]
<|image|>Continue parse the picture with markdown style: <md> |  | Mannose | Rhamnose | Glucuronic acid | Galacturonic acid | Glucose | Galactose | Xylose |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | 0 h | 0.84 | 0.19 | 0 | 0 |

[Assistant]
38.3 | 0.69 | 0.58 |
 | 3 h | 9.7 | 13.59 | 0 | 0.29 | 72.07 | 38.46 | 17.22 |
 | 6 h | 13.41 | 25.68 | 0 | 0.35 | 78.17 | 78 | 53.9 |
 | 9 h | 10.37 | 37.32 | 0 | 0.51 | 51.51 | 70.69 | 66.75 |
 | 12 h | 8.37 | 32.64 | 0 | 0.78 | 42.36 | 57.11 | 65.33 |
 | 15 h | 7.37 | 28.78 | 0 | 0.9 | 38.24 | 44.51 | 58.58 | </md>


[User] <|image|>Convert the picture into Markdown format.

[Assistant]
<md> |  | <COLSPAN=2> Entrance | <COLSPAN=2> Bragg peak |
 |  | KES | MPS | KES | MPS |
 | --- | --- | --- | --- | --- |
 | 100 MeV | 0.82 | 1.42 | 0.35 | 0.65 |
 | 160 MeV | 2.92 | 1.87 | 1.19 | 1.71 |
 | 230 MeV | 3.15 | 1.62 | 2.01 | 4.44 | </md>


[User] <|image|>Convert the diagram to Markdown syntax.

[Assistant]
<md> |  | No. of studies | No. of patients | HR (95%CI) | p-value | I2 (%) |
 | --- | --- | --- | --- | --- | --- |
 | Different Metastatic Positions |  |  |  |  |  |
 | Peritoneal Dissmination [26,29,36,37] | 4 | 832 | 0.76 (0.63, 0.92) | 0.005 | 68 |
 | Liver Metastasis [29,36,38] | 3 | 365 | 0.41 (0.30, 0.55) | <0.00001 | 23 |
 | Lymph Node Metastasis [29,36] | 2 | 155 | 0.36 (0.23, 0.59) | <0.00001 | 90 |
 | Different Regions |  |  |  |  |  |
 | Western Countries [27,30,32,35,39] | 5 | 639 | 0.65 (0.58, 0.73) | <0.00001 | 31 |
 | Asian Countries [26,29,31,33,34,36-38] | 8 | 2304 | 0.23 (0.17, 0.31) | <0.00001 | 93 | </md>


[User] <|image|>Parse the following content of the illustration in markdown code: <md> | Responses explaining the main benefit of participation | n (%) |

[Assistant]
| --- | --- |
 | Improves my household’s current livelihood or access to services | 61 (13.5) |
 | Important in times of emergency/in future | 73 (16.1) |
 | Benefits the community | 239 (52.8) |
 | Enjoyment/recreation | 8 (1.8) |
 | Spiritual, social status, self-esteem | 5 (1.1) |
 | Other | 67 (14.8) | </md>


[User]
<|image|>Parse the diagram content behind with markdown code: <md> | Risk factors | Patients with risk factors accounting for the population of SMM | Probability of 2-year progression to symptomatic MM |
 | --- |

[Assistant]
--- | --- |
 | Bone marrow plasma cells ≥ 60% | 2–10% | 90% |
 | Serum-free light-chain ratio ≥ 100 | 15% | 80% |
 | Abnormal magnetic resonance imaging (>1 focal lesion) | 15% | 70% |
 | High peripheral blood plasma cellsa | 15% | 70% | </md>


[User] <|image|>Express the photo as Markdown code.

[Assistant]
<md> | Gene name | Gene symbol | p value | FC |
 | --- | --- | --- | --- |
 | Non-SMC condensin I complex, subunit H | NCAPH | 1.46E−09 | 2.24 |
 | Polo-like kinase 1 | PLK1 | 1.54E−09 | 4.71 |
 | Cyclin A2 | CCNA2 | 1.94E−09 | 2.57 |
 | Serine/arginine-rich splicing factor 4 | SRSF4 | 1.15E−08 | −1.73 |
 | Protein regulator of cytokinesis 1 | PRC1 | 1.17E−08 | 2.17 |
 | TIMP metallopeptidase inhibitor 3 | TIMP3 | 1.24E−08 | 2.14 |
 | Lysine (K)-specific demethylase 5D | KDM5D | 2.59E−08 | 1.86 |
 | TPX2, microtubule-associated, homolog (Xenopus laevis) | TPX2 | 6.63E−08 | 2.64 |
 | Cell division cycle 20 homolog (S. cerevisiae) | CDC20 | 8.42E−08 | 3.08 |
 | Olfactory receptor, family 2, subfamily L, member 13 | OR2L13 | 9.20E−08 | −1.93 |
 | Prohibitin | PHB | 9.25E−08 | 1.99 |
 | ZW10 interactor | ZWINT | 9.82E−08 | 1.93 |
 | X-ray repair complementing defective repair in Chinese hamster cells 2 | XRCC2 | 1.44E−07 | 1.61 |
 | Brain expressed, X-linked 4 | BEX4 | 1.47E−07 | −1.76 |
 | Protein kinase, membrane associated tyrosine/threonine 1 | PKMYT1 | 1.61E−07 | 2.14 |
 | Golgin A8 family, member B | GOLGA8B | 1.62E−07 | −1.64 |
 | Holliday junction recognition protein | HJURP | 1.67E−07 | 2.55 |
 | S100 calcium binding protein A8 | S100A8 | 2.10E−07 | −5.24 |
 | TIMP metallopeptidase inhibitor 1 | TIMP1 | 6.34E−06 | 2.36 |
 | Chemokine (C–X–C motif) ligand 10 | CXCL10 | 2.04E−02 | 1.89 | </md>


[User] <|image|>Convert the picture into Markdown language.

[Assistant]
<md> | Level of care | Standard Zvandiri support | Enhanced Zvandiri support |
 | --- | --- | --- |
 | Eligibility criteria | • A viral load < 1000 copies/ml in last 6 months• CD4 count ≥ 200 cells/ml in last 6 months• Attending all scheduled clinic visits in last 3 months• Psychologically stable• Safe | • Commencing ART in past 3 months• A viral load ≥ 1000 copies/ml in the last 6 months• CD4 count < 200 cells/ml last 6 months• Pregnancy• Failing to attend ≥ 1 scheduled clinic visit(s) in last 3 months• Psychological distress• Abuse or neglect |
 | Intervention | • Monthly support group• Monthly home visit• Weekly SMS reminder• Zvandiri Centre contact• Caregiver workshop | • Monthly support group• Bi-weekly home visits• Daily SMS reminder• Weekly phone calls• Zvandiri Centre contact• Caregiver workshop• Referral and linkages• Community outreach visits | </md>


[User] <|image|>Convert the illustration to Markdown syntax.

[Assistant]
<md> | Axis | Direction | Conditions | Mean | SD | SEM (95% CI) | ICC (95% CI) | P value |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=3> X | <ROWSPAN=3> Anterior (+)/Posterior (−) | BL | 2.5 | 1.4 | 0.07 (0.02 to 0.27) | 0.999 (0.996 to 0.100) | <ROWSPAN=3> 0.10 |
 | SW | 2.4 | 1.4 | 0.03 (0.01 to 0.18) | 0.999 (0.998 to 0.100) |
 | RS | 2.1 | 1.2 | 0.04 (0.01 to 0.17) | 0.999 (0.998 to 0.100) |
 | <ROWSPAN=3> Y | <ROWSPAN=3> Superior (+)/Inferior (−) | BL | −1.4 | 1.2 | 0.03 (0.02 to 0.12) | 0.999 (0.998 to 0.100) | <ROWSPAN=3> 0.32 |
 | SW | −1.1 | 0.9 | 0.07 (0.04 to 0.41) | 0.993 (0.978 to 0.998) |
 | RS | −1.3 | 1.1 | 0.05 (0.04 to 0.25) | 0.997 (0.992 to 0.99.9) |
 | <ROWSPAN=3> Z | <ROWSPAN=3> Lateral (−)/Medial(+) | BL | −4.5 | 2.6 | 0.04 (0.01 to 0.18) | 0.100 (0.100 to 0.100) | <ROWSPAN=3> <0.001a |
 | SW | −2.9 | 2.6 | 0.06 (0.01 to 0.36) | 0.999 (0.998 to 0.100) |
 | RS | −4.4 | 2.7 | 0.05 (0.05 to 0.12) | 0.100 (0.999 to 0.100) | </md>


[User] <|image|>Render the illustration in Markdown format.

[Assistant]
<md> | <ROWSPAN=2> cells | <COLSPAN=2> Compound/IC50 |
 | Cisplatin (uM) | NVP-BEZ235 (nM) |
 | --- | --- | --- |
 | U2OS | 10.793 ± 0.097 | 198.433 ± 0.981 |
 | Saos-2 | 15.643 ± 0.193 | 197.800 ± 1.778 |
 | MG-63 | 7.873 ± 0.161 | 88.03 ± 0.531 | </md>


[User]
<|image|>Parse the image content behind with markdown code: <md> |  | Study population (n = 185) | Israeli experts in Family Medicine (n = 1901) | Israeli physicians working as primary care physicians (n = 4627) |
 | --- | --- | --- | --- |
 | Gender | 56.9% Female | 56% Female | 45% Female |
 | Age | Average 45.4 ± 8.8 (Range 30-69) | 50.4% < 50a | 37% < 50a |
 | Country of Birth | 53.5% Israel | ND | 34.5% Israel |
 | <ROWSPAN=3> Country of MD training | 62.8% Israel | <ROWSPAN=3> ND | 35.7% Israel |
 | 17.8% Former USSR | 41.1% Former USSR |
 | 11.6% Europe/America | 24% Europe/America |
 | <ROWSPAN=3> Specialization | 66.4% Family Medicine | <ROWSPAN=3> Not relevant | 32% Family Medicine |
 | 16% Residents | 44% Non-specialists |
 | 17.6% Other specialization or non-specialists | 24% Other specialization (approx. 50% of whom are specialists in Internal Medicine) |
 | <ROWSPAN=3> Form of employment | 80% Employed | 62% Employed | <ROWSPAN=3> ND |
 | <ROWSPAN=2> 20% Self Employed | 6% Self Employed |
 | 32% Both |
 | <ROWSPAN=4> HMO | 44.4% Clalit | <ROWSPAN=4> ND | 52% Clalit |
 | 43% Maccabi | 25% Maccabi |
 | 11% Meuhedet | 13.6% Meuhedet |
 | 2.4% Leumit | 9%

[Assistant]
Leumit |
 | <ROWSPAN=4> Place of employment | 80% community clinic | <ROWSPAN=4> 79% community clinics | 39% community clinics |
 | 14% rural community clinic | <ROWSPAN=3> 54% hospitals |
 | 3.2% IDF military clinics |
 | 2.4% mostly in hospitals | </md>


[User]
<|image|>Parse the photo content behind with markdown code: <md> | <ROWSPAN=2> Strains | <ROWSPAN=2> REP-PCR group | <COLSPAN=4> Colistin + sulbactam | <COLSPAN=4> Colistin + fosfomycin |
 | FICI(Col) | FICI(Sul) | ΣFICI (Col + Sul) | Interpretation(Col + Sul) | FICI(Col) | FICI(Fos) | ΣFICI (Col + Fos) | Interpretation(Col + Fos) |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | AB 1 | A | 0.06 | 2 | 2.06 | Indifference | 0.5 | 0.5 | 1 | Additive |
 | AB 2 | A | 0.25 | 0.5 | 0.75 | Additive | 0.5 | 0.13 | 0.63 | Additive |
 | AB 4 | A | 0.13 | 0.25 | 0.38 | Synergism | 0.5 | 0.25 | 0.75 | Additive |
 | AB 6 | A | 0.5 | 0.06 | 0.56 | Additive | 0.5 | 0.25 | 0.75 | Additive |
 | AB 7 | A | 0.25 | 0.25 | 0.5 | Synergism | 0.25 | 0.13 | 0.38 | Synergism |
 | AB 13 | A | 0.13 | 0.5 | 0.63 | Additive | 0.13 | 1 | 1.13 | Indifference |
 | AB 14 | A | 0.5 | 0.5 | 1 | Additive | 0.5 | 0.5 | 1 | Additive |
 | AB 15 | A | 0.03 | 1 | 1.03 | Indifference | 0.13 | 0.25 | 0.38 | Synergism |
 | AB 3 | B | 0.5 | 0.5 | 1 | Additive | 1 | 0.25 | 1.25 | Indifference |
 | AB 5 | C | 0.13 | 1.0 | 1.13 | Indifference | 0.25 | 0.25 | 0.5 | Synergism |
 | AB 8 | D | 0.06 | 1 | 1.06 | Indifference | 0.25 | 0.5 | 0.75 | Additive |
 | AB 9 | E | 0.008 | 1 | 1.01 | Indifference | 0.03 | 0.25 | 0.28 | Synergism |

[Assistant]
 | AB 10 | F | 0.004 | 2 | 2.00 | Indifference | 0.02 | 1 | 1.02 | Indifference |
 | AB 11 | G | 1 | 0.004 | 1.004 | Indifference | 0.01 | 1 | 1.01 | Indifference |
 | AB 12 | H | 0.06 | 0.5 | 0.56 | Additive | 0.25 | 0.5 | 0.75 | Additive | </md>


[User] <|image|>Convert the diagram into Markdown language.

[Assistant]
<md> | Band position (cm-1) | Assignment |
 | --- | --- |
 | 1730 | C = O stretching vibration in acetyl groups of hemicelluloses |
 | 1600 | C = C stretching vibration in aromatic ring of lignin |
 | 1510 | C = C stretching vibration in aromatic ring of lignin |
 | 1421 | CH2 scissoring at C(6) in cellulose |
 | 1368 | Symmetric C–H bending in cellulose |
 | 1236 | C-O stretching vibration in lignin, xylan and ester groups |
 | 1100 | O-H association band in cellulose and hemicelluloses (associated with crystalline cellulose) |
 | 1030 | C-O stretching vibration in cellulose and hemicelluloses |
 | 974 | C-O stretching vibration in arabinosyl side chains in hemicellulose |
 | 895 | Glucose ring stretch, C1-H deformation | </md>


[User] <|image|>Render the picture in Markdown format.

[Assistant]
<md> | <ROWSPAN=2>  | <COLSPAN=4> PC health domain |
 | Urinary | Sexual | Bowel | Vitality, general health |
 | --- | --- | --- | --- | --- |
 | Symptom | Leaked urine, increased frequency, dysuria | Erectile dysfunction, compromised masculinity, poor libido, poor communication, unable to engage in sexual activity | Diarrhea, fecal incontinence, increased urgency to defecate, increased frequency, pain, hematochezia | Depression, fatigue, hot flashes, weight gain, metabolic syndrome |
 | Self-management strategy | Pelvic floor exercises (Kegels) [29–32]Bladder training (timed voiding) [33, 34]Fluid management (drinking) [35]Physical activity [36]Weight loss [37]Diet (avoid bladder irritants/caffeine) [38]Using a penile clamp [39]How to protect clothing and bedding [40] | Partner communicationMaking time for and enhancing intimacy [41]Creative intimacy (non-penile) [42–46]Having an orgasm without erection/avoiding climacturia [47–49]Reduce alcohol and tobacco [50, 51]Using a vacuum erection device [52–55] (NOTE: medical strategy following self-management approach) | Pelvic floor exercises (Kegels) [56, 57]Diet for softer stools (fiber) [58]Diet to avoid irritationProper fluid intakeReducing painful bowel mvtsUsing OTC medications [58]Managing stress [59] | Decrease fatigue [60, 61]ExerciseImprove mood/depressionDeal with weight changes [62]Deal with hot flashes [63]Evaluate breast or nipple tenderness | </md>


[User]
<|image|>What are the following illustration content in markdown style: <md> | Parameter | Sex | Geographic origin | Mean age | Mean age, female subgroup | Mean age, male subgroup | Case/ratio fatality |
 | --- | --- | --- | --- |

[Assistant]
--- | --- | --- |
 |  | 81 females (58%) | 76 from urban areas (54%) | <ROWSPAN=2> 35 years (min. 16 years; max. 71 years) | <ROWSPAN=2> 30 years (min. 16 years; max. 69 years) | <ROWSPAN=2> 39 years (min. 17 years; max. 71 years) | <ROWSPAN=2> 317/140 (44%) |
 |  | 59 males (42%) | 64 from rural areas (46%) | </md>


[User]
<|image|>Parse the table content behind with markdown code: <md> | Event | Screening/baseline | D1 | D2 | D3 | M1 | M3 | M6 | M12 |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Informed consent | X |  |  |  |  |  |  |  |
 | History/physical | X | X |  | X | X | X | X | X |
 | NYHA | X | X |  |  | X | X | X | X |
 | CCS | X | X |  |  | X | X | X | X |
 | ECG | X | X |  | X | X | X | X | X |
 | Biochemistry local laboratory | X | X | X

[Assistant]
| X | X | X | X | X |
 | Biomarkers | X | X |  |  | X | X | X | X |
 | HLA tissue typing | X |  |  |  |  |  |  |  |
 | HLA tissue antibodies | X |  |  |  | X | X | X | X |
 | 6-minute walking test | X |  |  |  |  | X | X | X |
 | Chest X-ray | X |  |  |  |  |  |  |  |
 | CCT | X |  |  |  |  |  | X | X |
 | KCCQ | X |  |  |  |  | X | X | X |
 | SAQ | X |  |  |  |  | X | X | X |
 | EQ5D3L | X |  |  |  |  | X | X | X |
 | NOGA mapping |  |  | X |  |  |  |  |  |
 | IMP injection |  |  | X |  |  |  |  |  |
 | Echocardiography | X |  | X |  |  |  | X |  |
 | Holter monitoring | X | X | X | X |  |  |  |  |
 | AE evaluation |  |  | X | X | X | X | X | X | </md>


[User] <|image|>Render the table in Markdown format.

[Assistant]
<md> |  | Patients completing Part 1 of ARMS questionnaire (N = 103) |
 | --- | --- |
 | Age, years, mean (SD) | 42.5 (11.2) |
 | Sex, n (%) |  |
 | Male | 14 (14) |
 | Female | 89 (86) |
 | Type of MS, n (%) | (n = 97*) |
 | RRMS | 95 (98) |
 | SPMS | 2 (2) | </md>


[User] <|image|>Transform the photo into Markdown format.

[Assistant]
<md> | SNP (dbSNP ID) | chr11 position | variant amino acid | minor allele frequency in chronic tinnitus | homozygous/heterozygous carriers of the minor allele (pHWE) |
 | --- | --- | --- | --- | --- |
 | g.15,002T>C | 74,168,599 | T4A | 0.000 | - |
 | g.15,041G>A | 74,168,560 | V17M | 0.000 | - |
 | g.15,108C>G (rs34604640) | 74,168,493 | P39R | 0.000 | - |
 | g.15,131C>G (rs17215444) | 74,168,470 | R47G | 0.000 | - |
 | g.15,150G>A | 74,168,451 | R53H | 0.000 | - |
 | g.15,190T>C (rs2270676) | 74,168,411 | F66F | 0.125 | 5/62 (0.788) |
 | g.15,220C>T (rs17221826) | 74,168,381 | I76I | 0.000 | - |
 | g.15,240G>A (rs17215437) | 74,168,361 | R83H | 0.005 | 0/3 (0.930) |
 | g.15,255G>A (rs17221833) | 74,168,346 | R88H | 0.000 | - |
 | g.15,288G>A | 74,168,313 | R99H | 0.000 | - |
 | g.15,321C>T (rs11822977) | 74,168,280 | - | 0.000 | - | </md>


[User] <|image|>Translate the image into Markdown format.

[Assistant]
<md> | Antibody concentration | Number of subjects | Percent |
 | --- | --- | --- |
 | <10 IU/ml | 25 | 21.9 |
 | ≥10 IU/ml and ≤ 100IU/ml | 28 | 24.6 |
 | > 100IU/ml | 61 | 53.5 |
 | Total | 114 | 100 | </md>


[User]
<|image|>What are the following diagram content in markdown style: <md> |  | <COLSPAN=2> US1 | <COLSPAN=2> US2 |
 |  | Valence | Arousal | Valence | Arousal |
 | --- | --- | --- |

[Assistant]
--- | --- |
 | Exp I | 3.00 (±0.29) | 3.15 (±1.26) | 6.77 (±0.33) | 5.08 (±1.47) |
 | Exp II Group 1 | 4.44 (±0.43) | 2.38 (±0.85) | 6.50 (±0.74) | 4.56 (±1.63) |
 | Exp II Group 2 | 4.45 (±0.45) | 2.50 (±0.71) | 6.60 (±0.74) | 4.40 (±1.05) | </md>


[User] <|image|>Convert the figure into Markdown format.

[Assistant]
<md> | Missing | n(%) |
 | --- | --- |
 | ER | 16,247 (9.0%) |
 | PR | 21,306 (11.8%) |
 | HER2* | 45,021 (24.9%) |
 | Tumor grade | 10,594 (5.9%) |
 | Unknown cause of death | 2,386 (1.5%) |
 | Total cases with one or more of the above variables missing† | 57,695 (31.9%) |
 | Total cases with complete data | 123,395 (68.1%) | </md>


[User] <|image|>Interpret the figure as Markdown format.

[Assistant]
<md> |  | Focus genes | Interacting genes | Score | Top functions |
 | --- | --- | --- | --- | --- |
 | 1 | ACTA1, ACTA2 (includes EG:59), ARL1, ATP2B4, CNN1, DCBLD2, FGF2, HOXA10, ITGA5, ITGB3, MAP2K1, SEC13, SHOC2, SRF, TNC | Actin, Akt, Alpha actin, ERK, ERK1/2, FSH, IKK, Integrin, Jnk, Mapk, Mek, Pdgf, PDGF BB, PI3K, Pkc(s), PLC gamma, Pld, Ras, Tgf beta, Vegf | 31 | cellular assembly and organization, cell-to-cell signaling and interaction, viral infection |
 | 2 | CDCP1, CROT, DYX1C1, ERLIN2, GCOM1, GLS, GPR137B, HIST2H2AA3, PPM1K, SLAIN2, SPOCD1, TTC39A, TUBB3, ZDHHC2 | beta-estradiol, F2, HSPA1A, HSPA1L, IFRD2, KYNU, MAPK11 PREDICTED, VCP, MFHAS1, MMD, NFRKB, NOS3, PGLYRP1, SAMD4A, SLC16A5, SPR, TNF, TXN2, YWHAZ, ZDHHC8, ZNF267 | 28 | cardiovascular system development and function, tissue morphology, organismal development |
 | 3 | ACADL, ACADSB, CPEB3, ENTPD7, EVI5, CFI, CPA4, TLR3 GATM, LIPH GBP3, RFK, PPP1R9A, OSTM1 | 9330129D05RIK, ACAD8, ACAD9, ACAD10, ACAD11, Acyl-CoA dehydrogenase, C3, CDKN2A, CFHR3, CFHR5, F Actin, Glycogen synthase, GTP, heparin, IL4, IWS1, NFkB, NFYB, Pka, PLK1, RAB1A | 28 | lipid metabolism, molecular transport, small molecule biochemistry |
 | 4 | DCP2, FABP5, GLT8D3, HIST1H1C, HIST1H2BK, NASP, NUPL1, PCDH7, PPP1R3B, SEPX1, TM9SF4, UBE2N | ANXA9, DHX8, ERLIN1, FASTKD2, HNF4A, IL1B, MGEA5, MRTO4, NAT13, NUDT11, NUP62, OTUD7B, PHPT1, PSMC3, REXO2, SEC11A, MEM176B, TMEM189-UBE2V1, TRAF6, TRAFD1, Ube2n-Ube2v1, UHRF1, WRNIP1 | 23 | cell signaling, cancer, cellular compromise | </md>


[User] <|image|>Interpret the photo as Markdown format.

[Assistant]
<md> | Independent Predictors for Higher rHU | OR (95% CI) | p |
 | --- | --- | --- |
 | Use of Antiplatelets | 4.24 (1.10–16.3) | 0.036 |
 | Erythrocyte Count | 0.18 (0.05–0.55) | 0.003 |
 | Thrombocyte Count | 0.99 (0.98–0.99) | 0.029 |
 | Vessel Affected (M1 vs. M2) | 9.03 (1.36–59.73) | 0.022 |
 | History of Atrial Fibrillation | 2.96 (1.07–8.20) | 0.036 | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> | Locus | N | Na | Ho | He | HWE | FIS | NE‐2P | Null alleles | Error rate |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | CC141 | 50 | 3 | 0.400 | 0.369 | Ns | −0.073 | 0.842 | −0.042 | 0.009 |
 | CM72 | 50 | 5 | 0.460 | 0.570 | Ns | 0.202 | 0.713 | 0.020 | 0.026 |
 | EIM12 | 50 | 10 | 0.800 | 0.845 | Ns | 0.064 | 0.307 | −0.012 | 0.049 |
 | HKB24 | 50 | 7 | 0.560 | 0.564 | Ns | 0.016 | 0.669 | −0.010 | 0.012 |
 | EIM11 | 50 | 10 | 0.780 | 0.825 | Ns | 0.065 | 0.341 | −0.020 | 0.012 |
 | EIM31 | 50 | 10 | 0.760 | 0.728 | Ns |

[Assistant]
−0.034 | 0.500 | 0.004 | 0.013 |
 | HKB25 | 50 | 3 | 0.080 | 0.078 | Ns | −0.021 | 0.961 | −0.025 | 0.009 |
 | CC117 | 50 | 9 | 0.720 | 0.743 | Ns | 0.041 | 0.473 | 0.007 | 0.047 |
 | EIM17 | 50 | 6 | 0.740 | 0.735 | Ns | 0.004 | 0.496 | −0.24 | 0.012 |
 | EIM6 | 50 | 13 | 0.898 | 0.788 | Ns | −0.129 | 0.392 | −0.068 | 0.082 |
 | EI8 | 50 | 8 | 0.686 | 0.720 | Ns | 0.052 | 0.519 | −0.031 | 0.026 |
 | HKB32 | 50 | 3 | 0.060 | 0.059 | Ns | −0.014 | 0.971 | −0.008 | 0.002 |
 | Across all loci |  | 7.25 (±0.29) | 0.57 (±0.28) | 0.58 (±0.08) | Ns | 0.01 (±0.08) | 0.00093 | 0.004 (±0.04) | 0.025 (±0.02) | </md>


[User] <|image|>Transform the picture into Markdown format.

[Assistant]
<md> | Variable | Mean ± SD | N (%) |
 | --- | --- | --- |
 | Cluster 1 (social-demographic) |  |  |
 | Age (years) | 31.4 ± 9.2 |  |
 | 16-25 |  | 125 (8.7) |
 | 26-35 |  | 564 (39.2) |
 | 36-45 |  | 398 (27.7) |
 | ≥46 |  | 351 (24.4) |
 | Marital status, married (yes) |  | 997 (69.3) |
 | Medical insurance (yes) |  | 1211 (84.2) |
 | Education |  |  |
 | Primary school or lower |  | 290 (20.2) |
 | Middle school |  | 846 (58.8) |
 | High school or above |  | 302 (21.0) |
 | Duration of employment (years) | 2.2 ± 3.0 |  |
 | <5.0 |  | 1273 (88.5) |
 | 5.0 ~ 9.9 |  | 111 (7.7) |
 | ≥10.0 |  | 54 (3.8) |
 | Cluster 2 (health-related) |  |  |
 | Recent-month self-reported morbidity |  | 973 (67.7) |
 | Body mass index (BMI) | 22.4 ± 3.4 |  |
 | <18.5 (Underweight) |  | 139 (9.7) |
 | 18.5-23.9 (Normal weight) |  | 932 (64.8) |
 | 24.0-27.9 (Overweight) |  | 262 (18.2) |
 | ≥28.0 (Obese) |  | 105 (7.3) |
 | Chronic diseases |  |  |
 | 0 |  | 1318 (91.7) |
 | 1 or more |  | 120 (8.3) |
 | Cluster 3 (HRQOL domain scores) |  |  |
 | Physical functioning (PF) | 93.8 ± 10.9 |  |
 | Role physical (RP) | 85.9 ± 25.6 |  |
 | Bodily pain (BP) | 85.1 ± 16.6 |  |
 | General health (GH) | 70.6 ± 18.5 |  |
 | Vitality (VT) | 71.4 ± 18.0 |  |
 | Social functioning (SF) | 89.9 ± 14.2 |  |
 | Role-emotional (RE) | 82.0 ± 28.1 |  |
 | Mental health (MH) | 78.4 ± 15.2 |  |
 | Outcomes |  |  |
 | Recent 2-week physician visit |  |  |
 | 0 |  | 1319 (91.7) |
 | 1 or more |  | 119 (8.3) |
 | Hospitalization in the last year |  | 88 (6.1) |
 | 0 |  | 1350 (93.9) |
 | 1 or more |  | 88 (6.1) | </md>


[User] <|image|>Convert the figure into Markdown language.

[Assistant]
<md> | 1. | Have you ever heard of Vitamin D? (If you answered 'No', please go to Q9) |
 | --- | --- |
 | 2. | Do you think vitamin D is important for your health? |
 | 3. | Have you ever been told that you have vitamin D deficiency (not enough vitamin D)? |
 | 4. | Do you take vitamin D supplements (tablets)? |
 | 5. | Do you include vitamin D rich foods such as milk, fish oil or eggs in your meal? |
 | 6. | Have you been out in the sun within the last year with exposed face, arms or legs whenever possible? |
 | 7. | Do you know that vitamin D deficiency causes tiredness, low mood as well as muscle and bone pain? |
 | 8. | Where did you hear about vitamin D? |
 | 9. | Which sex are you? (If you are male, please go to Q11) |
 | 10. | Are you pregnant or breast feeding? |
 | 11. | What is your age? |
 | 12. | How do you think we can make patients of this surgery know more about vitamin D? | </md>


[User] <|image|>Render the illustration in Markdown format.

[Assistant]
<md> | ICF components and domains | All (N = 433) | Men (N = 166) | Women (N = 267) | Gender difference, p-value |
 | --- | --- | --- | --- | --- |
 | Body functions | 361 (83.4) | 138 (83,1) | 223 (83,5) | 1 |
 | 1. Mental functions | 219 (50.6) | 73 (44) | 146 (54.7) | .03* |
 | Body structures | 83 (19.2) | 39 (23.5) | 44 (16.8) | .07 |
 | 1. Structures of the nervous system | 6 (1.4) | 5 (3) | 1 (0.4) | .03* |
 | 7. Structures related to Movements | 61 (14.1) | 32(19.3) | 29 (10.9) | .01* |
 | Activities and participation | 152 (35.1) | 54 (32.5) | 98 (36.7) | .38 |
 | 2. General tasks and demands | 65 (15) | 16 (9.6) | 50 (18.7) | .01* | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> | <COLSPAN=5> ICSI Q3 score |
 | --- | --- | --- | --- | --- |
 | <ROWSPAN=2> Baseline frequency | <ROWSPAN=2> N | <COLSPAN=3> End point (week 14) |
 | 1 | 2 | 3 |
 | 2 | 7 | 1 | 6 | - |
 | 3 | 10 |

[Assistant]
1 | 7 | 2 |
 | 4 | 0 | - | - | - |
 | ≥5 | 1 | - | - | 1 | </md>


[User] <|image|>Transcribe the image into Markdown format.

[Assistant]
<md> | Variables | Response | Number | % |
 | --- | --- | --- | --- |
 | <ROWSPAN=2> Drank chlorine treated water | No | 132 | 73.3 |
 | Yes | 48 | 26.7 |
 | <ROWSPAN=2> Had latrine | No | 84 | 46.7 |
 | Yes | 96 | 53.3 |
 | <ROWSPAN=2> Hand wash after toilet | No | 148 | 82.2 |
 | Yes | 32 | 17.8 |
 | <ROWSPAN=2> Walking barefoot | No | 40 | 22.2 |
 | Yes | 140 | 77.8 |
 | <ROWSPAN=2> Took deworming from the last 1 month to the last 1 year | No | 134 | 74.4 |
 | Yes | 46 | 25.6 |
 | <ROWSPAN=2> Iron supplementation | No | 110 | 61.1 |
 | Yes | 70 | 38.9 |
 | <ROWSPAN=2> Open field defecation | No | 18 | 10.0 |
 | Yes | 162 | 90.0 |
 | <ROWSPAN=2> Water contact | No | 30 | 16.7 |
 | Yes | 150 | 83.3 | </md>


[User] <|image|>Render the photo in Markdown format.

[Assistant]
<md> |  |  | <COLSPAN=3> Pre | <COLSPAN=3> 2 week | <COLSPAN=3> 4 week | <COLSPAN=3> 6 week |
 |  |  | <COLSPAN=3> (%) | <COLSPAN=3> (%) | <COLSPAN=3> (%) | <COLSPAN=3> (%) |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=6> Control (n = 4) | C16:0 | 10.7 | ± | 1.1 | 9.5 | ± | 0.9 | 9.8 | ± | 1.1 | 10.5 | ± | 0.6 |
 | C16:1n-7 | 6.6 | ± | 1.3 | 7.3 | ± | 0.3 | 7.1 | ± | 0.5 | 7.2 | ± | 0.4 |
 | C18:0 | 14.8 | ± | 0.9 | 16.1 | ± | 1.3 | 15.6 | ± | 1.1 | 14.5 | ± | 0.3a |
 | C18:1n-9 | 20.6 | ± | 3.2 | 20.8 | ± | 3.1 | 20.0 | ± | 2.4b | 19.8 | ± | 0.8c |
 | C18:2n-6 | 38.6 | ± | 2.3 | 38.5 | ± | 3.1 | 39.4 | ± | 4.2d | 40.5 | ± | 1.4e |
 | C20:4n-6 | 7.7 | ± | 0.3 | 7.3 | ± | 0.8 | 8.5 | ± | 2.1 | 6.7 | ± | 0.7f |
 | <ROWSPAN=6> HF (n = 8) | C16:0 | 10.5 | ± | 0.6 | 10.1 | ± | 0.8 | 10.2 | ± | 0.8 | 10.8 | ± | 1.1 |
 | C16:1n-7 | 5.9 | ± | 1.4 | 7.7 | ± | 2.7 | 6.4 | ± | 2.0 | 6.4 | ± | 1.7 |
 | C18:0 | 14.7 | ± | 1.0 | 14.9 | ± | 1.1 | 15.5 | ± | 0.7 | 15.5 | ± | 0.9*a |
 | C18:1n-9 | 18.8 | ± | 2.0 | 28.1 | ± | 3.4** | 25.1 | ± | 1.0**b | 24.6 | ± | 1.6**c |
 | C18:2n-6 | 34.4 | ± | 3.8 | 31.3 | ± | 4.7* | 32.0 | ± | 2.9*d | 31.0 | ± | 2.8**e |
 | C20:4n-6 | 12.2 | ± | 4.6 | 8.7 | ± | 1.4** | 11.2 | ± | 1.6 | 10.5 | ± | 2.0f | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> |  | Non-BSCM | BSCM | Significancep-value |
 | ---

[Assistant]
| --- | --- | --- |
 | n | 125 | 125 |  |
 | Score | -12.26 | -12.34 | 2.40E-003 |
 | Improved Score | 75/125 | 50/125 | 9.84E-003 |
 | Mean p-value | 0.129 | 0.109 | 2.20E-016 |
 | cMonkey Version | 4.8.2 | 4.8.2 |  | </md>


[User]
<|image|>What are the following table content in markdown style: <md> | Type of Health Facility | <COLSPAN=2> Peshawar | <COLSPAN=2> Faisalabad |
 |  | Total Number | Number included in study | Total Number | Number included in study |
 | --- | --- | --- | --- | --- |
 | District headquarter Hospital | 01 | 01 | 01 | 01 |
 | Taluka headquarter Hospital | 0 | 0 | 04 |

[Assistant]
04 |
 | Rural Health Centre | 04 | 03 | 11 | 00 |
 | Basic Health Unit | 56 | 14 | 168 | 03 |
 | Maternal & Child Health Centre | 01 | 01 | 06 | 02 |
 | Dispensaries | 12 | 3 | 108 | 10 |
 | Total | 74 | 22 | 298 | 20 | </md>


[User]
<|image|>Continue parse the diagram with markdown style: <md> | GO pathways* | Number of genes | Number of TFs† | Number of TF/Number of genes‡ | Number of FFLs§ |
 | --- | --- | --- | --- | --- |
 | Top five with the highest total number of TFs |  |  |  |  |
 | Response to other organisms | 296 | 2,249 | 7.6 | 9,865 |
 | Secondary metabolic process | 284 | 1,964 | 6.9 | 3,321 |
 | Response to temperature stimulus | 238 | 1,650 | 6.9 | 10,151 |
 | Anatomical structure morphogenesis | 291 | 1,537 | 5.3 | 13,275 |
 | Response to radiation | 250 | 1,524 | 6.1 | 6,233 |
 | Top five with the lowest total number of TFs |  |  |  |  |
 | Glycerophospholipid metabolic process | 21 | 38 | 1.8 | 69 |
 | Sulfur amino acid biosynthetic process | 24 | 60 | 2.5 | 13 |
 | Gametophyte development | 24 | 62 | 2.6 | 1 |
 | Cellular morphogenesis in differentiation | 25 | 68 | 2.7

[Assistant]
| 78 |
 | Indole and derivative metabolic process | 22 | 71 | 3.2 | 46 |
 | Top five with the highest relative number of TFs |  |  |  |  |
 | Defense response to fungus | 26 | 355 | 13.7 | 4,353 |
 | Photosynthesis | 80 | 1,064 | 13.3 | 2,459 |
 | Response to light intensity | 26 | 334 | 12.8 | 2,652 |
 | Chlorophyll biosynthetic process | 22 | 243 | 11.0 | 443 |
 | Porphyrin biosynthetic process | 39 | 421 | 10.8 | 754 |
 | Top five with the lowest relative number of TFs |  |  |  |  |
 | Glycerophospolipic metabolic process | 21 | 38 | 1.8 | 0 |
 | Membrane lipid biosynthetic process | 48 | 111 | 2.3 | 121 |
 | Sulfur compound biosynthetic process | 32 | 75 | 2.3 | 98 |
 | Golgi vesicle transport | 44 | 104 | 2.4 | 47 |
 | Biogenic amine metabolic process | 32 | 76 | 2.4 | 53 | </md>


[User]
<|image|>Parse the photo content behind with markdown code: <md> |  | SVR (n = 75) | Non-SVR (n = 34) | P value* | OR for non-SVR (95% CI) |
 | --- | --- | --- | --- | --- |
 | Male sex, n (%) | 41 (55%) | 19 (56%) | 1 | 1.05 (0.46–2.37) |
 | Age, years (median) | 56 | 60 | 0.19 | 1.02 (0.99–1.07) |
 | BMI > 25, n (%) | 24 (32%) | 15 (44%) | 0.29 | 1.66 (0.73–3.86) |
 | HCV-1a, n (%) | 13 (18%) | 2 (6%) | 0.13 | 0.29 (0.06–1.40) |
 | High viral load, n (%)° | 44 (59%) | 25 (85%) | 0.2 | 1.95 (0.80–4.76) |
 | Cirrhosis, n (%) | 16 (21%)

[Assistant]
| 14 (41%) | 0.03 | 2.58 (1.07–6.21) |
 | PegIFN alfa-2a, n (%) | 38 (51%) | 12 (41%) | 0.15 | 0.53 (0.23–1.22) | </md>


[User]
<|image|>Continue parse the diagram with markdown style: <md> | ASKAS | Variables | Coefficient | p value | R2* |
 | --- | --- | --- | --- | --- |
 | Knowledge |

[Assistant]
Male x Female | -4.81 | <0.0001 | 0.1436 |
 |  | Employed x Unemployed | -1.96 | 0.0359 |  |
 | Attitudes | Education x illiterate | -2.82 | 0.0066 | 0.0638 |
 |  | Age (55-59 years old x ≥60 years old) | -2.15 | 0.0374 |  | </md>


[User] <|image|>Convert the photo to Markdown syntax.

[Assistant]
<md> |  | Total An. sundaicus captured | Mean catch per night | Trap efficacy (compared to HLC) |
 | --- | --- | --- | --- |
 | <COLSPAN=4> Indoor traps |
 | HLC in | 827 | 51.7 | – |
 | CDC-LT | 41 | 2.6 | 0.05 |
 | Resting box in | 2 | 0.1 | 0.00 |
 | Resting jar in | 3 | 0.2 | 0.00 |
 | <COLSPAN=4> Outdoor traps |
 | HLC out | 1277 | 79.8 | – |
 | Large tent | 104 | 6.5 | 0.08 |
 | Small tent | 82 | 5.1 | 0.06 |
 | ITT | 13 | 0.8 | 0.01 |
 | Resting box out | 2 | 0.1 | 0.00 |
 | Resting jar out | 2 | 0.1 | 0.00 | </md>


[User] <|image|>Render the diagram in Markdown format.

[Assistant]
<md> |  | β | SE | z value | p |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> Daily data |
 | Intercept | −22.3142 | 0.5200 | −42.9118 | < 0.0001 |
 | D0,0 | 1.0901 | 0.0281 | 38.8183 | < 0.0001 |
 | D85,85 | 0.6453 | 0.0216 | 29.8125 | < 0.0001 |
 | T0,0 | 0.0441 | 0.0037 | 11.8177 | < 0.0001 |
 | T12,1 | −0.0751 | 0.0065 | −11.5170 | < 0.0001 |
 | P0,0 | 0.0044 | 0.0013 | 3.4509 | 0.0006 |
 | P51,16 | 0.0990 | 0.0081 | 12.2828 | < 0.0001 |
 | H0,0 | −0.0131 | 0.0013 | −10.2594 | < 0.0001 |
 | H38,1 | 0.0453 | 0.0027 | 17.0574 | < 0.0001 |
 | W119,86 | −0.5238 | 0.0325 | −16.1039 | < 0.0001 |
 | <COLSPAN=5> Weekly data |
 | Intercept | −22.4553 | 1.4451 | −15.5389 | < 0.0001 |
 | D0,0 | 1.1318 | 0.0820 | 13.8066 | < 0.0001 |
 | D13,13 | 0.6034 | 0.0551 | 10.9537 | < 0.0001 |
 | T0,0 | 0.0386 | 0.0150 | 2.5816 | 0.0098 |
 | T1,1 | −0.0612 | 0.0148 | −4.1208 | < 0.0001 |
 | P7,3 | 0.1036 | 0.0208 | 4.9686 | < 0.0001 |
 | H4,1 | 0.0354 | 0.0061 | 5.7550 | < 0.0001 |
 | W17,12 | −0.5573 | 0.0940 | −5.9315 | < 0.0001 | </md>


[User]
<|image|>What are the following table content in markdown style: <md> | Foods | EPA + DHA (g/100g) | EPA (g/100g) | DHA (g/100g) |
 | --- | --- | --- | --- |
 | Salmon | 1.95 | 1.01 | 0.94 |
 | Herring | 1.66 | 0.97 | 0.69 |
 | Anchovy | 1.45 | 0.54 | 0.91 |
 | Mackerel | 1.30 | 0.90 | 1.40 |
 | Trout

[Assistant]
| 0.73 | 0.20 | 0.53 |
 | Swordfish | 0.76 | 0.11 | 0.65 |
 | Sea bass | 0.60 | 0.24 | 0.36 |
 | Squid | 0.49 | 0.15 | 0.34 |
 | Mussel | 0.44 | 0.19 | 0.25 |
 | Sole | 0.25 | 0.14 | 0.11 |
 | Cod | 0.18 | 0.06 | 0.12 | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> | Subscale | Minimum | Maximum | Mean | SD | Skewness | Kurtosis |
 | --- | --- | --- | --- | --- | --- | --- |
 | Living conditions and lifestyle (7 items) |  |  |  |  |  |  |
 | Raw and unscaled | 7 | 35 | 25.31 | 5.24 | −0.73 | 3.56 |
 | Rescaled but unweighted for importance | 0 | 100 | 65.41 | 18.74 | 0.73 | 3.56 |
 | Rescaled and weighted for importance | 0 | 100 | 53.82 | 16.46 | 0.16 | 2.84 |
 | Social relationships (5 items) |  |  |  |  |  |  |
 | Raw

[Assistant]
and unscaled | 5 | 25 | 19.19 | 3.66 | −1.16 | 5.11 |
 | Rescaled but unweighted for importance | 0 | 100 | 70.94 | 18.31 | −1.16 | 5.11 |
 | Rescaled and weighted for importance | 0 | 100 | 64.00 | 15.92 | −0.17 | 3.56 |
 | Personal independence (5 items) |  |  |  |  |  |  |
 | Raw and unscaled | 5 | 25 | 15.47 | 4.37 | −0.29 | 2.59 |
 | Rescaled but unweighted for importance | 0 | 100 | 52.33 | 21.86 | −0.29 | 2.59 |
 | Rescaled and weighted for importance | 0 | 100 | 58.97 | 17.95 | −0.02 | 2.96 | </md>


[User]
<|image|>Continue parse the picture with markdown style: <md> | Contrast | gSAD (n = 29) | HC (n = 27) | t (df = 56) | p |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> Accuracy |
 | Attend Angry vs. Shapes | 85.6 ± 11.8 | 86.6 ± 10.9 | 0.31 | 0.76 |
 | Attend Fear vs. Shapes | 92.7 ± 9.1 | 90.7 ± 10.1 | 0.75 | 0.46 |
 | Attend Happy vs. Shapes | 90.8 ± 11.0 | 86.3 ± 14.2 | 1.34 | 0.19 |
 | Attend Shapes vs. Angry (distractor) | 94.1 ± 8.1 | 93.7 ± 8.0 | 0.20 | 0.84 |
 | Attend Shapes vs. Fear (distractor) | 90.1 ± 14.4 | 95.5 ± 7.6 | 1.75 | 0.09 |
 | Attend Shapes vs. Happy (distractor) | 91.2 ± 11.5 | 93.4 ± 7.5 | 0.81 | 0.42 |
 | <COLSPAN=5> Reaction Times |
 | Attend Angry vs. Shapes | 1479.6 ± 405.8 | 1419.9 ± 219.5 | 0.68 | 0.50 |
 | Attend Fear vs.

[Assistant]
Shapes | 1337.9 ± 371.9 | 1285.7 ± 218.5 | 0.63 | 0.53 |
 | Attend Happy vs. Shapes | 1303.7 ± 340.4 | 1231.0 ± 207.4 | 0.96 | 0.34 |
 | Attend Shapes vs. Angry (distractor) | 1021.1 ± 273.5 | 957.8 ± 122.4 | 1.11 | 0.27 |
 | Attend Shapes vs. Fear (distractor) | 985.4 ± 239.9 | 946.2 ± 144.4 | 0.74 | 0.47 |
 | Attend Shapes vs. Happy (distractor) | 975.6 ± 236.4 | 944.3 ± 157.7 | 0.58 | 0.57 | </md>


[User] <|image|>Convert the diagram to Markdown syntax.

[Assistant]
<md> |  | Family assessment form (n = 159) | Patients (n = 136) |
 | --- | --- | --- |
 | Yes | 13 (8%) | 11 (8%) |
 | No | 79 (50%) | 70 (52%) |
 | Not registered | 67 (42%) | 55 (40%) | </md>


[User]
<|image|>Parse the picture content behind with markdown code: <md> |  | <COLSPAN=2> Saline control | <COLSPAN=2> Bevacizumab treatment |
 |  | Pre | Post | Pre | Post |
 | --- | --- | --- | --- | --- |
 | Tumor volume, range (mm3) | 7.34–36.9 | 9.20–58.2 | 6.96–46.8 | 8.13–44.5 |
 | Tumor volume, mean ± sd (mm3) | 14.7 ± 9.4 | 22.7 ± 15.7 | 16.1 ± 13.2 | 17.8 ± 12.3 |
 | R1, range (ms–1) | 0.45–0.54 | 0.42–0.55 | 0.45–0.57 | 0.49–0.59 |
 | R1, mean ±

[Assistant]
sd (ms–1) | 0.53 ± 0.03 | 0.50 ± 0.04 | 0.53 ± 0.04 | 0.54 ± 0.04 |
 | Steady-state rCBV, range | 0.76–2.89 | 0.63–1.63 | 0.92–1.61 | 0.63–1.55 |
 | Steady-state rCBV, mean ± sd | 1.45 ± 0.83 | 1.17 ± 0.45 | 1.20 ± 0.26 | 0.93 ± 0.26 |
 | Ktrans, range (min–1) | 0.027–0.084 | 0.026–0.084 | 0.016–0.064 | 0.014–0.054 |
 | Ktrans, mean ± sd (min–1) | 0.047 ± 0.018 | 0.056 ± 0.018 | 0.043 ± 0.016 | 0.031 ± 0.014 | </md>


[User] <|image|>Transform the figure into Markdown format.

[Assistant]
<md> | Vaccine | Estimated annual deaths (95% CI) [A] | Estimated vaccine effectiveness (range) [B] | Estimated annual deaths preventable by vaccination (95% CI) [C]* | Estimated vaccine coverage in Haiti (%) [D]5 | Estimated vaccine preventable deaths in Haiti (range) [E]† |
 | --- | --- | --- | --- | --- | --- |
 | Hib | 1,56526 (906–2,203) | 95%30 | 1,487 (861–2,093) | 75 | 1,115 (646–1,570) |
 | Hepatitis B | 3,48027 | 95%27 | 3,306 | 75 | 2,480 |
 | Rotavirus | 800 (710–889)28 | 60% (50–70%)31 | 480 (426–533) | 60 | 288 (256–320) |
 | PCV | 2,98726 (2,061–3,287) | 60% (50–70%)32 | 1,792 (1,237–1,972) | 75 | 1,344 (928–1,479) |
 | Total | 8,832 | – | 7,065 | – | 5,227 | </md>


[User]
<|image|>Parse the picture content behind with markdown code: <md> | Characteristic | Schizophrenia (n = 43) | Healthy control (n = 54) |
 | --- | --- | --- |
 | Years of education: mean ± SD (range) | 12.67 ± 1.91 (9–17) | 14.09 ± 2.02 (10–20)⁎ |
 | Years of parental education: mean ± SD (range) | 14.87 ± 2.30 (10–19) | 14.28 ± 2.44 (8–20) |
 | Gender: n males (%) | 34 (79%) | 35 (65%) |
 | Ethnicity: n Caucasian (%) | 22 (51%) | 28 (52%) |
 | Handedness: n left-handed (%) | 0 (0%) | 4 (7%) |
 | WASI IQ: mean ± SD (range) | 102.12 ± 13.10 (78–131) | 113.63 ± 10.67 (85–135)⁎ |
 | Diagnosis: n (%) |  |  |
 | Schizophrenia | 41 (96%) | – |
 | Schizoaffective | 1 (2%) | – |
 | Schizophreniform | 1 (2%) | – |
 | Medication status: n (%) |  |  |
 | Unmedicated | 15 (35%) | – |
 | Atypical antipsychotic | 27 (63%) | – |
 | Typical and atypical antipsychotic | 1 (2%) | – |
 | Symptom scores: mean ± SD (range) |  |  |
 | Disorganization symptoms | 7.03 ± 3.53 (3–16) | – |
 |

[Assistant]
Reality distortion symptoms | 16.07 ± 6.18 (4–29) | – |
 | Poverty symptoms | 13.49 ± 5.69 (3–26) | – |
 | Behavioral data |  |  |
 | AX-CPT accuracy: mean ± SD |  |  |
 | AX | .94 ± .08 | .98 ± .03 |
 | AY | .82 ± .21 | .84 ± .19 |
 | BX | .86 ± .14 | .94 ± .08 |
 | BY | .98 ± .04 | .99 ± .03 |
 | AX-CPT reaction time: mean (ms) ± SD |  |  |
 | AX | 613 ± 184 | 545 ± 122 |
 | AY | 774 ± 180 | 711 ± 148 |
 | BX | 761 ± 302 | 625 ± 219 |
 | BY | 664 ± 224 | 560 ± 164 |
 | Stroop accuracy: mean ± SD |  |  |
 | Congruent | .97 ± .03 | .99 ± .02 |
 | Incongruent | .92 ± .11 | .95 ± .06 |
 | Stroop reaction time: mean (ms) ± SD |  |  |
 | Congruent | 685 ± 131 | 622 ± 85 |
 | Incongruent | 785 ± 158 | 717 ± 120 | </md>


[User] <|image|>Express the image as Markdown code.

[Assistant]
<md> | Gene | Forward primer | Reverse primer |
 | --- | --- | --- |
 | GAPDH | CAAGCTCATTTCCTGGTATGACA | GCCTCTCTTGCTCAGTGTCC |
 | ACC | CCAGCAGATTGCCAACATC | ACTTCGGTACCTCTGCACCA |
 | TLR4 | TCCAGCCACTGAAGTTCT | CAGCAAAGTCCCTGATGA |
 | TNF-α | TCTACTGAACTTCGGGGTGA | GATCTGAGTGTGAGGGTCTGG |
 | IL-1Ra | GCAAGATGCAAGCCTTCAGA | CCTTGTAAGTACCCAGCAATGA | </md>


[User] <|image|>Transform the illustration into Markdown format.

[Assistant]
<md> |  | Enrolled (N = 63) baseline | Dropouts (N = 21) baseline | COmpleters (N = 42) baseline | Completers (N = 42) 1 year follow-up |
 | --- | --- | --- | --- | --- |
 | Days with headaches per month | 22.2 (6.5) | 23.1 (6.9) | 21.7 (6.4) | 11.2 (7.4) |
 | Tablets per month | 33.0 (23.2) | 38.8 (25.1) | 30.1 (21.9) | 15.0 (16.6) |
 | MIDAS total score | 68.9 (49.9) | 79.0 (58.3) | 68.8 (45.0) | 38.6 (38.9) |
 | Intensity of headache on VAS | 7.7 (1.6) | 8.1 (1.4) | 7.6 (1.7) | 6.5 (1.7) |
 | HAM-A Score | 12.8 (7.6) | 13.3 (8.8) | 12.6 (7.1) | 11.6 (6.9) |
 | HAM-D Score | 12.4 (7.2) | 12.4 (7.1) | 12.4 (7.4) | 9.8 (5.9) |
 | SDS Score | 8.6 (2.2) | 8.8 (2.3) | 8.6 (2.1) | 5.7 (3.2) |
 | SCI-SUBS total score | 12.2 (9.1) | 11.1 (7.5) | 5.6 (3.3) | 7.9 (7.9) | </md>


[User] <|image|>Continue parse the picture with markdown style: <md> | pH | Average | Standard Deviation |

[Assistant]
 | --- | --- | --- |
 | 3.04 | −1.42 | 0.87 |
 | 5.25 | −11.40 | 4.35 |
 | 6.99 | −16.83 | 1.40 |
 | 10.12 | −35.07 | 2.74 | </md>


[User]
<|image|>Parse the table content behind with markdown code: <md> | Subgroup | RR all Antibody Prophyaxis | # of Studies | # in Treatment Groups |
 | --- | --- | --- | --- |
 | Premature <35 weeks GA[11,12,15] | 0.29 (0.16,

[Assistant]
0.54) | 3 | 624 |
 | Chronic Lung Disease (CLD)[11,12,15] | 0.55 (0.38, 0.80) | 3 | 696 |
 | Congenital Heart Disease (CHD)[11,12,16] | 0.56 (0.40, 0.79) | 3 | 865 | </md>


[User] <|image|>Translate the illustration into Markdown format.

[Assistant]
<md> |  | <COLSPAN=2> Univariable | <COLSPAN=2> Multivariable |
 | Characteristic | OR (95% CI) | P-value* | OR (95% CI) | P-value* |
 | --- | --- | --- | --- | --- |
 | History of STI during pregnancy | 1.5 (0.7–3.3) | 0.29 | 4.0 (1.7–9.6) | 0.002 |
 | Cesarean delivery | 4.8 (3.3–7.0) | < 0.001 | 2.9 (1.8–4.8) | < 0.001 |
 | Number of days admitted to hospital | 1.4 (1.3–1.5) | < 0.001 | 1.2 (1.1–1.4) | < 0.001 |
 | Formal employment | 0.5 (0.3–0.7) | < 0.001 | 0.5 (0.3–0.8) | 0.002 |
 | Multiparous | 0.6 (0.4–0.7) | < 0.001 | 0.5 (0.3–0.7) | 0.001 |
 | Residence in Mbarara municipality | 0.6 (0.4–0.8) | 0.001 | 0.7 (0.5–1.1) | 0.11 |
 | Number of vaginal exams in labor | 1.0 (0.9–1.1) | 1.0 | 0.9 (0.8–1.0) | 0.06 |
 | HIV-infected | 1.0 (0.6–1.6) | 1.0 | 1.0 (0.5–1.9) | 0.94 |
 | Age | 0.9 (0.9–1.0) | < 0.001 | 1.0 (0.9–1.0) | 0.40 |
 | Number of hours in labor | 1.0 (1.0–1.0) | 0.08 | 1.0 (1.0–1.0) | 0.95 |
 | Referred from an outside facility | 2.6 (1.8–3.7) | < 0.001 | 1.5 (0.9–2.4) | 0.10 | </md>


[User] <|image|>Encode the picture in Markdown syntax.

[Assistant]
<md> | Treatment phase | Adverse event | No. of patients |
 | --- | --- | --- |
 | <ROWSPAN=6> T1 | Swelling | 1 |
 | Itching | 1 |
 | Fever | 4 |
 | Throat infection | 1 |
 | Chest Congestion | 2 |
 | Total | 9 |
 | <ROWSPAN=3> T2 | Diarrhea | 1 |
 | Body Pain | 1 |
 | Total | 2 |
 | <ROWSPAN=2> T3 | Diarrhea | 1 |
 | Total | 1 |
 | T4 | Nil | - | </md>


[User]
<|image|>Continue parse the picture with markdown style: <md> | <ROWSPAN=2> Standard level | <ROWSPAN=2> Mass of mix stock (g) | <ROWSPAN=2> Final mass (g) | <COLSPAN=2> Concentration (ppm) |
 | GL | DGuA |
 | --- | --- | --- | --- | --- |
 | SL1 | NA | NA | 0 | 0 |
 | SL2 | 0.117 | 10.019 | 1.3 | 3.58 |
 | SL3 | 0.229 | 10.592 | 2.39 | 6.62 |
 | SL4 | 0.518 | 10.037

[Assistant]
| 5.71 | 15.81 |
 | SL5 | 1.006 | 10.027 | 11.11 | 30.75 |
 | SL6 | 2.011 | 10.072 | 22.12 | 61.19 |
 | SL7 | 4.033 | 10.001 | 44.62 | 123.47 | </md>


[User] <|image|>Transcribe the illustration into Markdown format.

[Assistant]
<md> | Selected variables | Categories | P | OR | 95%CI |
 | --- | --- | --- | --- | --- |
 | Education | Continuous variable (years) | < 0.001 | 0.410 | 0.356-0.473 |
 | <ROWSPAN=2> Gender | Male (Ref.) | --- | 1.00 | --- |
 | Female | < 0.001 | 2.43 | 1.51-3.89 | </md>


[User]
<|image|>Parse the following content of the figure in markdown code: <md> |  | <COLSPAN=7> Phenotype and functionality of the infusion products | <COLSPAN=3> Clinical outcome |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Patient number | Infused cells | CD8+ | CD45RO+ | CCR7+ | CD27+ | Reactivitya | Total number of responding CD8+T cells infused | Response | TTP | OS |
 |  | (x 1010) | (%) | (%) | (%) | (% of CD8) | (%) | (x 106) | (RECIST) | (mo) | (mo) |
 | 1 | 2.9 | 94 | 99.7 | 7.5 | 6.1 | 28.8# | 6460 | CR | 30+ | 30+ |
 | 2 | 1.8 | 92 | 97.4 | 4.9 | 5.2 | 1.0# | 175 | PD | 2 | 7 |
 | 3 | 2.0 | 95 | 99.4 | 6.1 | 0.5 |

[Assistant]
0.0# | 7 | SD | 4 | 11.5 |
 | 6 | 0.3 | 47 | 98.4 | 3.9 | 1.2 | 0.9* | 41 | PD | 2 | 4.6 |
 | 7 | 1.3 | 88 | 89 | 31.8 | 3.4 | 0.4# | 44 | SD | 5 | 11 |
 | 11 | 7.5 | 95 | 99 | 0.6 | 8.1 | 6.0* | 4377 | CR | 10+ | 10+ | </md>


[User] <|image|>Convert the illustration into Markdown language.

[Assistant]
<md> |  | EEG frequency matched mean Fisher's r (SEM) | EEG frequency different mean Fisher's r (SEM) | P value |
 | --- | --- | --- | --- |
 | SICI | 1.388 (0.135) | 0.615 (0.199) | 0.01 |
 | ICF | 0.961 (0.168) | 1.177 (0.401) | 0.583 |
 | Single pulse | 0.227 (0.262) | 0.544 (0.214) | 0.730 | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | Variable | Estimate (mo) | SE | 95% CI | p-value |
 | --- | --- | --- | --- | --- |
 | Gender (female) | 15.7 | 0.56 | 14.6–16.8 | 0.28 |
 | Age (< 60) | 15.0

[Assistant]
| 0.62 | 13.8–16.2 | 0.15 |
 | Histology (epidermoid) | 16.6 | 0.58 | 15.4–17.7 | 0.16 |
 | T-stage (3–4) | 16.9 | 0.63 | 15.6–18.4 | 0.92 |
 | N-stage (2–3) | 16.2 | 0.65 | 15.0–17.5 | 0.07 | </md>


[User] <|image|>Transform the figure into Markdown format.

[Assistant]
<md> |  | Gaussian-Like | Triangle | Multi-Label with Equal Description Degrees |
 | --- | --- | --- | --- |
 | MAE (Ori) | 5.320 | 5.366 | 5.69 |
 | MAE (Str 1) | 5.159 | 5.170 | 5.137 |
 | MAE (Str 2) | 5.127 | 5.148 | 5.127 |
 | MAE (Str 3) | 5.112 | 5.178 | 5.530 |
 | MAE (Str 4) | 5.089 | 5.229 | 5.528 |
 | MAE (Str 5) | 4.920 | 4.925 | 5.002 | </md>


[User] <|image|>Transform the figure into Markdown format.

[Assistant]
<md> | Number | Gender/age (y) | Organ involvement | SLEDAI | Site of CVST occlusion | Treatment | Outcome |
 | --- | --- | --- | --- | --- | --- | --- |
 | 1 | F/16 | F, K, H | 21 | SSS, (B) TS, (B) SS | GC (pulse) + CTX | Lost |
 | 2 | F/18 | F, K, H, C | 25 | (L) TS | GC (pulse) + CTX | Died |
 | 3 | F/17 | F, R, A, K | 22 | (R) TS, (R) SS | GC + CTX | Died |
 | 4 | F/20 | F, H | 15 | SSS | GC (pulse) + CTX | Survived |
 | 5 | M/38 | H, K | 20 | SSS, (B) TS, (B) SS | GC (pulse) + CTX + FK506 | Survived |
 | 6 | F/36 | R, A, H, C, P | 17 | (L) TS, (L) SS | GC + CTX | Survived |
 | 7 | F/43 | R, A, S | 18 | SSS, (L) TS | GC + CTX | Survived |
 | 8 | F/52 | A, K, S | 19 | (R) ISS, (L) TS | GC (pulse) + CTX | Survived |
 | 9 | F/30 | F, K, P | 24 | (R) SS, (R) TS | GC (pulse) + CTX | Survived |
 | 10 | F/20 | S, K, H, TTP | 30 | SSS, (L) TS | GC (pulse) + CTX + MMF + plasmapheresis | Survived |
 | 11 | M/30 | None | 16 | SSS, (B) TS | GC (pulse) + CTX | Survived |
 | 12 | M/14 | F, GI, K | 20 | (R) SS | GC (pulse) + CTX | Survived |
 | 13 | F/41 | R, A, K | 18 | (B) TS, (B) SS | GC (pulse) + CTX | Died |
 | 14 | M/28 | K, A | 20 | (L) SS, (L) TS | GC (pulse) + CTX | Survived |
 | 15 | F/30 | R, H | 17 | (R) TS | GC + CTX | Survived |
 | 16 | M/34 | K | 20 | (L) SS | GC (pulse) + CTX | Survived |
 | 17 | F/15 | K, CAPS | 19 | SSS | GC (pulse) + CTX | Survived | </md>


[User]
<|image|>Continue parse the diagram with markdown style: <md> |  |  | <COLSPAN=4> ActiGraph activity levels and measurements |
 |  |  | ActiGraph-min (moderate min) | ActiGraph-min (vigorous min) | ActiGraph-min | ActiGraph-count |
 | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=2> Respondent characteristics\IPAQ activity level | Moderate | Vigorous | Total MET | Total MET |
 | Sex |  |  |  |  |  |
 |  | Male | 0.10* | 0.23*** | 0.14*** | 0.18*** |
 |  | Female | 0.09* | 0.09* | 0.09* | 0.15*** |
 | Age, years |  |  |  |  |  |

[Assistant]
|  | ≤29 | 0.05 | 0.21*** | 0.06 | 0.04 |
 |  | 30-49 | 0.09* | 0.12** | 0.12** | 0.19*** |
 |  | ≥ 50 | 0.12* | 0.14** | 0.15** | 0.25*** |
 | Full-time worker |  |  |  |  |  |
 |  | Yes - high PD | 0.19* | 0.25** | 0.18* | 0.16 |
 |  | Yes - low PD | 0.10* | 0.10** | 0.12** | 0.20*** |
 |  | Not full-time | 0.06 | 0.21*** | 0.07 | 0.08 |
 | Tertiary education |  |  |  |  |  |
 |  | Yes | 0.03 | 0.17** | 0.09 | 0.08 |
 |  | No | 0.11*** | 0.17*** | 0.12*** | 0.18*** |
 | BMI |  |  |  |  |  |
 |  | Overweight (≥ 25) | 0.10 | 0.22*** | 0.14** | 0.21*** |
 |  | Normal (< 25) | 0.09** | 0.14*** | 0.10** | 0.14*** |
 | VFL, % |  |  |  |  |  |
 |  | Overweight (≥ 10) | 0.18*** | 0.23*** | 0.24*** | 0.31*** |
 |  | Normal (< 10) | 0.08* | 0.10** | 0.09* | 0.14*** | </md>


[User]
<|image|>Continue parse the image with markdown style: <md> |  | No transfection | Control plasmid | siRNA |
 | --- | --- | --- | --- |
 | End1/E6E7 cells | M1:3.26 ± 0.12 | 5.12 ± 0.18 | 5.32 ± 0.16 |
 |  | M2:72.68 ± 3.52 | 71.96 ± 3.26 |

[Assistant]
72.38 ± 3.45 |
 |  | M3:11.32 ± 0.68 | 10.84 ± 0.62 | 11.24 ± 0.63 |
 |  | M4:12.74 ± 0.72 | 12.08 ± 0.70 | 11.06 ± 0.66 |
 | HeLa cells | M1:4.07 ± 0.16 | 4.62 ± 0.23 | 5.57 ± 0.21 |
 |  | M2:54.24 ± 2.36 | 55.36 ± 2.75 | 69.02 ± 2.98 |
 |  | M3:15.71 ± 0.78 | 15.84 ± 0.81 | 15.93 ± 0.84 |
 |  | M4:25.98 ± 1.24 | 24.18 ± 1.16 | 9.48 ± 0.56 | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | <ROWSPAN=2> Plant species | <COLSPAN=4> aIC50 (μg/mL) |
 | DPPH scavenging activity | Inhibitory activity against lipid peroxidation | Metal chelating activity | Hydroxyl radical scavenging activity |
 | --- | --- | --- | --- | --- |
 | Methanol extract | 34.45 ± 1.15 | 35.36 ± 1.68 | 45.91 ± 0.88 | 89.11 ± 0.29 |
 | Chloroform extract | 31.34 ± 1.10 | 29.31 ± 0.65 |

[Assistant]
39.46 ± 0.78 | 83.34 ± 0.35 |
 | Gallic acid | 3.79 ± 0.69 | 255.43 ± 11.68 | — | 59.14 ± 1.10 |
 | Ascorbic acid | 6.05 ± 0.34 | >1000 | — | 160.55 ± 2.31 |
 | BHT | 15.61 ± 1.26 | 1.00 ± 0.23 | — | 33.92 ± 0.79 |
 | α-Tocopherol | — | 0.48 ± 0.05 | — | — | </md>


[User]
<|image|>Parse the following content of the image in markdown code: <md> | <ROWSPAN=2> Case no. | <COLSPAN=2> Recurrence or metastasis after pancreatic resection | <ROWSPAN=2> Postoperative observation period (months) |
 | Location

[Assistant]
| Treatment |
 | --- | --- | --- | --- |
 | 1 | Bilateral lung | None (BSC) | 131a |
 | 2 | Bilateral lung | IFN + IL-2 + UFT | 108a |
 | 3 | – | – | 138 |
 | 4 | – | – | 49 |
 | 5 | Bilateral lung | Sunitinib | 8 |
 | 6 | – | – | 8 |
 | 7 | – | – | 3 |
 | 8 | – | – | 39 |
 | 9 | Bilateral lung, bone | Dacarbazine | 4a | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> |  | normal n = 14 | hypertrophic n = 14 | p |
 | --- | --- | --- | --- |
 | LW/BW ratio | 5.534 ± 0.08274 | 5.396 ±

[Assistant]
0.04775 | 0.190 |
 | LiW/BW ratio | 44.13 ± 0.3586 | 44.02 ± 0.3085 | 0.8272 | </md>


[User]
<|image|>What are the following illustration content in markdown style: <md> | Participant Demographics (N = 151) | %a |
 | --- | --- |
 | <COLSPAN=2> Age |
 | 16–17 years | 18.83 |
 | 25–54 years | 54.54 |
 | 55–64 years | 25.97 |
 | <COLSPAN=2> Gender |
 | Male | 44.16 |
 | Female | 53.9 |
 | Transgender | 1.3 |
 | Canadian born | 61.04 |
 | <COLSPAN=2> Education |

[Assistant]
 | Some high school | 26.62 |
 | High school graduate or equivalent | 16.23 |
 | Some college/university | 24.03 |
 | Bachelor’s degree | 20.13 |
 | Graduate degree | 9.74 | </md>


[User] <|image|>Render the photo in Markdown format.

[Assistant]
<md> |  | Head | Eye/Ear/Face | Chest/Back | Upper Limb | Lower Limb | Other | Total |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | Abrasions | 0.8 | 0.8 | 0.8 | 2.5 | 5 | 0.8 | 10.7 |
 | Lacerations | 5.8 | 3.3 | 0.8 | 28.1 | 18.2 | 0.8 | 57.0 |
 | Puncture wounds | 2.5 | 0.8 | 0.8 | 3.3 | 5 | 0.8 | 13.2 |
 | Amputations | 0 | 0 | 0 | 2.5 | 0 | 0 | 2.5 |
 | Dislocations | 0 | 0.8 | 0 | 0 | 3.3 | 0.8 | 4.9 |
 | Fractures | 0 | 0 | 0.8 | 0.8 | 0 | 0.8 | 2.4 |
 | Other | 0 | 2.5 | 2.5 | 0.8 | 0 | 3.3 | 9.1 |
 | Total | 9.1 | 8.2 | 5.7 | 38 | 31.5 | 7.3 | 100 | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | Variable | Group | DFB | DFBstderr | Probt |
 | --- | --- | --- | --- | --- |
 | <ROWSPAN=2> SIDa(mEq/L) | Octanoate | -2.157 | 0.927 | P < 0.001 |
 | Normal saline | -6.413 | 0.948 | P < 0.001 |
 | <ROWSPAN=2> SIDe(mEq/L) | Octanoate | -0.288 | 0.409 | P < 0.001 |
 | Normal saline |

[Assistant]
-3.242 | 0.422 | P < 0.001 |
 | <ROWSPAN=2> SIG(mEq/L) | Octanoate | -1.866 | 0.996 | P = 0.068 |
 | Normal saline | -3.167 | 1.019 | P = 0.068 | </md>


[User] <|image|>Transform the illustration into Markdown format.

[Assistant]
<md> | Species | Testing pairs | <COLSPAN=6> ACC(%) |
 |  |  | MMI + NMBAC | MMI | NMBAC | You’s work [18] | Huang’s work [19] | Zhou’s work [14] |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | E.coli | 6954 | 92.80 | 89.01 | 90.13 | 89.30 | 66.08 | 71.24 |
 | C.elegans | 4013 | 92.16 | 88.54 | 86.72 | 87.71 | 81.19 | 75.73 |
 | human1412 | 1412 | 94.33 | 91.31 | 90.23 | 94.19 | 82.22 | 76.27 |
 | H.pylori | 1420 | 91.13 | 90.28 | 90.34 | 90.99 | 82.18 | N/A a |
 | M.musculus | 313 | 95.85 | 92.01 | 91.37 | 91.96 | 79.87 | 76.68 | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> |  | Controls | UC | CD | Allergy colitis | P |
 | --- | --- | --- | --- | --- | --- |
 | pANCA (+) (%) | — | 25 | 10.5 | 17.6 | .04* |
 | cANCA (+) (%) | — | 10 | — | — | .04** |
 |

[Assistant]
IgA ASCA (+) (%) | 4.3 | 7.5 | 57.9 | 17.6 | <.00001*** |
 | IgG ASCA (+) (%) | 4.3 | 17.5 | 71.1 | 29.4 | <.00001**** |
 | ASCA IgG and/or IgA (%) | 8.7 | 17.5 | 73.7 | 29.4 | <.00001***** |
 | Combinations ANCA and ASCA (%) |  |  |  |  | <.00001****** |
 | pANCA(+)ASCA(+) | 0 | 2.5 | 5.3 | 0 |  |
 | pANCA(+)ASCA(−) | 0 | 22.5 | 5.3 | 17.7 |  |
 | pANCA(−)ASCA(+) | 8.7 | 15 | 68.4 | 29.4 |  |
 | pANCA(−)ASCA(−) | 91.3 | 60 | 21.1 | 52.9 |  | </md>


[User]
<|image|>Parse the table content behind with markdown code: <md> | Author | Year | Sample size | Male/female | age | Results |
 | --- | --- | --- | --- | --- | --- |
 | Sumiko [27] | 2016 | 82 | 50/32 | 64.6 | OS LFS |
 | Joji [28] | 2017 | 42 | 23/19 | 73 | OS |
 | Paola [20] | 2015 | 86 | 49/37 | NA | OS LFS |
 | Hideto [26] | 2010 | 80 | 53/27 | 70 | OS LFS |
 | Jae-Ho [37] | 2015 | 82 | 53/29 |

[Assistant]
49 | OS CIR |
 | Mo XD [36] | 2016 | 78 | 48/30 | 38 | CIR | </md>


[User] <|image|>Express the image as Markdown code.

[Assistant]
<md> | Item | Baseline | Week 2 | Week 4 | Week 8 | P (2,0) | P (4,0) | P (8.0) |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | Pain severity |  |  |  |  |  |  |  |
 | With tenderness | 7.60 ± 1.14 | 3.60 ± 1.14 | 5.00 ± 0.71 | 5.60 ± 1.14 | < 0.001 | < 0.001 | < 0.001 |
 | Without tenderness | 7.21 ± 1.03 | 3.47 ± 1.43 | 4.63 ± 1.38 | 5.21 ± 1.03 | < 0.001 | < 0.001 | < 0.001 |
 | p-value | 0.515 | 0.840 | 0.425 | 0.515 | < 0.001 | < 0.001 | < 0.001 |
 | Pain frequency |  |  |  |  | < 0.001 | < 0.001 | < 0.001 |
 | With tenderness | 14.40 ± 1.34 | 7.40 ± 2.41 | 9.00 ± 2.12 | 1.00 ± 1.58 | < 0.001 | < 0.001 | < 0.001 |
 | Without tenderness | 11.58 ± 3.73 | 6.26 ± 1.63 | 7.21 ± 1.96 | 9.47 ± 3.70 | < 0.001 | < 0.001 | < 0.001 |
 | p-value | 0.067 | 0.364 | 0.140 | 0.242 | < 0.001 | < 0.001 | < 0.001 |
 | Drug use |  |  |  |  | < 0.001 | < 0.001 | < 0.001 |
 | With tenderness | 14.60 ± 1.34 | 7.00 ± 1.22 | 9.00 ± 1.22 | 12.60 ± 1.34 | < 0.001 | < 0.001 | < 0.001 |
 | Without tenderness | 12.21 ± 3.10 | 6.05 ± 1.93 | 7.47 ± 2.34 | 10.21 ± 3.10 | < 0.001 | < 0.001 | < 0.001 |
 | p-value | 0.111 | 0.208 | 0.069 | 0.111 | < 0.001 | < 0.001 | < 0.001 | </md>


[User] <|image|>Convert the illustration to Markdown syntax.

[Assistant]
<md> |  | <COLSPAN=2> Gender | <COLSPAN=2> Age group |
 |  | Girls(N = 67) | Boys(N = 68) | 6-years-old(N = 71) | 7-years-old(N = 62) |
 | --- | --- | --- | --- | --- |
 | Food responsiveness | 1.8 (0.5) | 2.0 (0.6) | 1.8 (0.5) | 2.0 (0.6) |
 | Enjoyment of food | 3.5 (0.6) | 3.3 (0.7) | 3.4 (0.7) | 3.4 (0.7) |
 | Emotional overeating | 1.3 (0.4) | 1.6 (0.5) | 1.4 (0.5) | 1.5 (0.5) |
 | Desire to drink | 2.3 (0.8) | 2.5 (0.7) | 2.3 (0.7) | 2.5 (0.8) |
 | Satiety responsiveness | 2.8 (0.6) | 2.8 (0.7) | 2.8 (0.7) | 2.8 (0.6) |
 | Slowness in eating | 2.6 (0.6) | 2.8 (0.8) | 2.8 (0.7) | 2.6 (0.7) |
 | Emotional undereating | 2.2 (0.8) | 2.3 (0.8) | 2.2 (0.8) | 2.3 (0.8) |
 | Food fussiness | 2.6 (0.9) | 3.1 (0.9) | 2.9 (0.9) | 2.8 (0.9) | </md>


[User] <|image|>Convert the illustration into Markdown language.

[Assistant]
<md> |  | <COLSPAN=2> Flexion phase | <COLSPAN=2> Extension phase |
 |  | ANOVA | Post-hoc comparisons | ANOVA | Post-hoc comparisons |
 |  | P value | (Tuckey-Kramer) | P value | (Tuckey-Kramer) |
 | --- | --- | --- | --- | --- |
 | Interval* |  | Between conditions |  | Between conditions |
 | 1 | <0.001 | 1 > all; 2 > 3,4; 5 > 4 | <0.001 | 1,5 > 3,4; 2 > 4 |
 | 2 | <0.001 | 1 > all; 2,3,5 > 4 | 0.011 | 1 > 4 |
 | 3 | 0.009 | 1 > 2,4,5 | 0.004 | 1 > 2,4,5 |
 | 4 | 0.084 | / | 0.135 | / |
 | Condition† |  | Between intervals |  | Between intervals |
 | 1 | <0.001 | 1,2 > 3 > 4 | <0.001 | 1,2 > 3 > 4 |
 | 2 | <0.001 | 1 > 3,4; 2 > 4 | <0.001 | 1,2 > 3 > 4 |
 | 3 | <0.001 | 1,2,3 > 4 | <0.001 | 1,2 > 3 > 4 |
 | 4 | 0.027 | 1 > 4 | <0.001 | 1,2 > 3 > 4 |
 | 5 | <0.001 | 1 > 3,4; 2 > 4 | <0.001 | 1 > 2 > 3 > 4 | </md>


[User]
<|image|>What are the following picture content in markdown style: <md> | Variable | BL | BLF | Ramadan |
 | --- | --- | --- | --- |
 | Total sleep time (min) | 6.2 ± 0.8 | 6.1 ± 1.0 | 5.9 ± 0.7 |
 | Sleep Latency | 29.6 ± 24.2 | 33.7 ± 33.6 | 32.8 ± 29.3 |
 | REM Latency | 80.6 ± 26.9 | 108.9 ± 47.8 | 73.5 ± 40.1 |
 | Stage N1% | 5.2 ± 2.6 | 6.2 ± 3.7 | 5.5 ± 2.4 |
 | Stage N2% | 58.7 ± 4.6 | 65.1 ± 5.3 | 65.2 ± 6.1 |
 | Stage N3% | 10.7 ± 6.3 | 11.0 ± 6.1 | 10.7 ± 7.1 |
 | Stage REM% | 25.6 ± 4.8 | 17.7 ± 8.1* | 18.6 ± 10.7* |
 | REM cycles | 4.1 ± 1 | 3.9 ± 0.9 | 3.8 ± 1.3 |
 |

[Assistant]
Stage shifts | 69.3 ± 14.8 | 73.5 ± 19.5 | 69.1 ± 16.3 |
 | Arousal Index | 8.5 ± 3.9 | 9.1 ± 3.8 | 8.9 ± 3.6 | </md>


[User] <|image|>Express the picture as Markdown code.

[Assistant]
<md> | <COLSPAN=2>  | Number | Percent |
 | --- | --- | --- | --- |
 | <ROWSPAN=2> Gender | Female | 15 | 57.69 |
 | Male | 11 | 42.31 |
 | <ROWSPAN=2> Age group | 65–74 | 10 | 38.46 |
 | 75+ | 16 | 61.54 |
 | <ROWSPAN=3> Prescribed medicines | ≤6 | 7 | 26.92 |
 | 7–10 | 8 | 30.77 |
 | 11+ | 11 | 42.31 |
 | <ROWSPAN=3> Long-term conditions | 2–3 | 7 | 26.92 |
 | 4–5 | 7 | 26.92 |
 | 6+ | 12 | 46.15 |
 | <ROWSPAN=2> Requires mobility aid | Yes | 9 | 34.62 |
 | No | 17 | 65.38 |
 | <ROWSPAN=3> Living status | Alone | 7 | 26.92 |
 | With partner | 16 | 61.54 |
 | With family member | 3 | 11.54 |
 | <ROWSPAN=3> Index of Multiple Deprivation (IMD) Decilea | 1–2 | 9 | 34.62 |
 | 3–4 | 12 | 46.15 |
 | 5+ | 4 | 15.38 |
 | <COLSPAN=2> Total number of patients | 26 | 100.00 | </md>


[User]
<|image|>Parse the diagram content behind with markdown code: <md> | Region | Hemisphere | Cluster size | Peak voxel (x) | Peak voxel (y) | Peak voxel (z) | Maximum Z-value |
 | --- | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=7> HABITUATION EFFECT OF THE STRESSFUL TASK

[Assistant]
|
 | Cerebellum crus I | R | 13957 | 28 | −80 | −22 | 4.36 |
 | amygdala | L |  | −28 | −6 | −14 | 3.74 |
 | hippocampus | L |  | −32 | −26 | −11 | 3.01 |
 | temporal pole | L |  | −42 | −12 | −30 | 4 |
 |  | R |  | 40 | 0 | −36 | 3.92 |
 | cerebellum vermis | L |  | −6 | −49 | −23 | 3.28 |
 | fusiform gyrus | L |  | −28 | −56 | −6 | 3.52 |
 |  | R |  | 36 | −36 | 19 | 2.87 |
 | Lateral parietal cortex | R | 1801 | 32 | −70 | 54 | 3.47 |
 | <COLSPAN=7> HABITUATION EFFECT OF THE MINDFUL BREATHING TASK |
 | Midbrain | L | 1862 | −6 | −16 | −16 | 4.7 |
 | midbrain | R |  | 6 | −10 | −12 | 3.7 |
 | pons | R |  | 2 | −20 | −24 | 4.25 |
 | thalamus | L |  | −20 | −20 | −10 | 3.71 |
 | hippocampus | L |  | −40 | −20 | −16 | 3.73 | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> |  | <COLSPAN=3> Hazard Ratio |
 |  | Estimate | 95% CI | p value** |
 | --- | --- | --- | --- |
 | Treatment Groups |  |  |  |
 | SRS* | <COLSPAN=3> reference |
 | Surgery + SRS | 0.68 | 0.49-0.94 | 0.020 |
 | WBRT + SRS | 0.99 | 0.93-1.05 | 0.660 |
 | Surgery + WBRT + SRS | 0.79 | 0.61-1.02 | 0.070 |
 | WBRT | 1.94 | 1.37-2.73 | <0.001 |
 | Surgery + WBRT | 1.04 | 0.76-1.43 | 0.800 |
 | Age at diagnosis |  |  |  |
 | <65* | <COLSPAN=3> reference |

[Assistant]
| ≥65 | 1.21 | 0.91-1.62 | 0.190 |
 | ECOG-PS |  |  |  |
 | 0* | <COLSPAN=3> reference |
 | 1 | 1.07 | 0.58-1.95 | 0.830 |
 | 2 | 1.67 | 1.02-2.72 | 0.040 |
 | 3 | 4.58 | 4.28-4.91 | <0.001 |
 | 4 | 11.26 | 5.98-21.2 | <0.001 |
 | Primary Tumor Histology |  |  |  |
 | NSCLC* | <COLSPAN=3> reference |
 | SCLC | 1.11 | 0.97-1.26 | 0.130 |
 | Breast | 0.87 | 0.78-0.96 | <0.001 |
 | Melanoma and Renal-cell | 1.17 | 1.06-1.3 | <0.001 |
 | Other | 1.41 | 0.95-2.1 | 0.080 | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | Theme | Quotationsa |
 | --- | --- |
 | Perceived risks of APOSTEL VI study | HCP06, gynaecologist-in-training: A pessary is low risk, because you don’t have the connection with the child.HCP03, gynaecologist-in-training:

[Assistant] We insert a device that is foreign to the body of which we know that it gives a local reaction, and if that is an inflammatory reaction it might just as well result in premature birth. So therefore it could also actually be a higher risk.HCP04, gynaecologist-in-training: Why would you do an intervention, why would we do something that has not been proven? I also wonder what the working mechanism of the pessary is, nobody can tell me, not even the big advocates.HCP14, gynaecologist: I don’t believe in the intervention at all, and luckily I don’t have to counsel for the study, but I do think that if you don’t know if something works the best way to find out is to conduct a study.PW03, participating in APOSTEL VI: They just don’t know if it [the pessary] results in an extended gestational time. But real risks, no I don’t think those were described.PW14, participating in APOSTEL VI: It’s very clear in the study that the risks are really very low, and that it won’t result in a premature birth which is the most important thing. | </md>


[User]
<|image|>Parse the image content behind with markdown code: <md> | Maternal characteristics | r value4 | P value |
 | --- | --- | --- |
 | Age (years) | 0.17 | 0.04 |
 | Weight (kg) | −0.11 | 0.18 |
 | Phytate : calcium1,2 | −0.11 | 0.18 |
 | Calcium (mg/d)1 | 0.09 | 0.25 |
 | Phosphorus (mg/d) | 0.10 | 0.20 |
 | Sun exposure index1,3 | 0.35 | <0.001 |
 | Time of day (24 hours) | −0.11 | 0.18 |
 |  | Mean (95% CI)5 | P value |
 | Hospital |  |  |
 | Private nursing home (n

[Assistant]
= 68) | 11.8 (10.8, 12.9) | <ROWSPAN=2> 0.002 |
 | Government (n = 82) | 9.8 (9.1, 10.6) |
 | Parity |  |  |
 | First pregnancy (n = 118) | 10.6 (9.9, 11.3) | <ROWSPAN=2> 0.71 |
 | >1 pregnancy (n = 32) | 10.9 (9.5, 12.5) | </md>


[User]
<|image|>Parse the picture content behind with markdown code: <md> | Characteristic | Category 1 | Category 2 | Category 3 | Total |
 | --- | --- | --- | --- | --- |
 | Preventiona | n = 34 | n = 862 | n = 1,485 | n = 2,381 |
 | Slept under ordinary net | 18(52.9) | 319(37.0) | 653(44.0) | 990(41.6) |
 | Slept under treated bed net | 17(50.0) | 549(63.7) | 749(50.4) | 1,315(55.2) |
 | Repellants | 5(14.7) | 128(14.8) | 152(10.2) | 285(12.0) |
 | Treated clothes | 1(2.9) | 70(8.1) | 97(6.5) | 168(7.1) |
 | Treated hammock | 0(0.0) | 75(8.7) | 84(5.7) | 159(6.7) |
 | Herbal decoctions | 1(2.9) | 48(5.6) | 74(5.0) | 123(5.2) |
 | Indigenous medicine | 2(5.9) | 77(8.9) | 96(6.5) | 175(7.3) |
 | <COLSPAN=5> Preferred measure a |
 | Slept under ordinary net | 14(41.2) | 116(13.5) | 263(17.7) | 393(16.5) |
 | Slept under treated net | 18(52.9) | 605(70.2) | 973(65.5) | 1,596(67.0) |
 | Repellants | 1(2.9) | 13(1.5) | 48(3.2) | 62(2.6) |
 | Treated clothes | 0(0.0) | 8(0.9) | 26(1.8) |

[Assistant]
34(1.4) |
 | Treated hammock | 0(0.0) | 14(1.6) | 11(0.7) | 25(1.0) |
 | Herbal decoctions | 0(0.0) | 6(0.7) | 16(1.1) | 22(0.9) |
 | Indigenous medicine | 0(0.0) | 20(2.3) | 59(4.0) | 79(3.3) | </md>


[User] <|image|>Render the table in Markdown format.

[Assistant]
<md> | Gene | Direction | Sequence (5′–3′) | Amplicon size (bp) |
 | --- | --- | --- | --- |
 | Agactin | Forward | CTTCCTGCCATATATGATTGG | 210 |
 |  | Reverse | GCCAGCACCTCGATCTTCATG |  |
 | AgPAL | Forward | AATAGACTTGAGGCATTTGGAGG | 121 |
 |  | Reverse | ACAGAATCTTGAGGGATGGAGTT |  |
 | AgC4H | Forward | TCCTGATTTGGCTAAAGATGT | 137 |
 |  | Reverse | TCTTCCTCCAATGCTCACTAT |  |
 | AgC3H | Forward | AAGAGGAGCTGGACCGGGTAA | 148 |
 |  | Reverse | TTGGCACTGGCTTTGTGAGGG |  |
 | AgF5H | Forward | CTTCATTCTTCCGCTGCTTAGTT | 136 |
 |  | Reverse | TTTAGCCAGTCCACGATGAGATA |  |
 | Ag4CL | Forward | GGCAACTTCTGAAACATTGGTAG | 131 |
 |  | Reverse | GGACCTGGTATCCCTTGTACTTTAT |  |
 | AgHCT | Forward | TTACTTCCTCCACTCCCACCA | 146 |
 |  | Reverse | TAATCATTGTCCATCCGTGCC |  |
 | AgCOMT | Forward | GATGAGGGAAAGGTAGTTGTTGC | 93 |
 |  | Reverse | ATAGGCGTCTAACTGAAGGACAG |  |
 | AgCCoAOMT | Forward | GGCTTCTAATGCTGAATCCAAAC | 129 |
 |  | Reverse | CTAAGCTCTTTCATTGCCTCTGG |  |
 | AgCCR | Forward | GCTGGGCTTTCTGGCTATTCT | 82 |
 |  | Reverse | TTGCTGCACATGCCTCGATTA |  |
 | AgCAD | Forward | GGCTACATAGCATCATGGCTTGT | 134 |
 |  | Reverse | TGAAGTCTATCCTTGGCTCCCTC |  |
 | AgPOD | Forward | TGTTGCTTTGGCGAATGGTCC | 98 |
 |  | Reverse | TAACATCCGGCATATCCTCTG |  | </md>


[User] <|image|>Render the photo in Markdown format.

[Assistant]
<md> |  | General population | Bedouin |
 | --- | --- | --- |
 | Female | 36.55±10.82* | 42.97±15.57* |
 | Male | 35.75 ±12.66& | 44.35±14.12& | </md>